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C HA PT E R  1
I N T R OD U C TI ON
“Everything should be tested and proved and then it becomes a part of scientific
medicine- old and new.” - Pandit Jawaharlal Nehru
“India can benefit enormously if it can build a golden triangle between traditional
medicine, modern medicine and modern science.” -Dr R.A Mashelkar Director CSIR
1.1 TOXICOLOGY
Toxicology is “the study of poisons”. Toxicology involves knowledge of
physiological, biochemical, and morphological effects of a chemical. This approach
of the physiological and biochemical understanding of toxicity was first used by the
famous French physiologist, Claud Bernard, more than 150 years ago. Toxicology
reflects the development of society a progression from simplicity to sophistication,
from crude to cultured from elemental to elegant and from taking lives to saving
lives.1
Toxic was originally tekw, a word meaning to run or flee, later becoming toxsa
in Persian and toxon in greek, meaning bow. The toxin meaning may have come from
the poison used to tip of the arrows, or as Robert graves suggested ,from the yew
tree(taxus) from which arrows were best made and whose berries where long known
to be poisonous. From this concept we can say that toxicology and plant system has a
distant relationship.
“Toxicology is defined as study of the adverse effects of chemical, physical
and biological agents on living organisms and the ecosystems, including the
prevention amelioration of side effects”.1
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1.1.1 RELATIONSHIP BETWEEN DOSE AND TOXICITY
Theophrastus Phillipus Auroleus Bombastus von Hohenheim (also referred to
as Paracelsus) is also considered "the father" of toxicology. He is credited with the
classic toxicology statement, "Alle Dinge sind Gift und nichts istohne Gift; allein die
Dosis macht, dass ein Ding kein Gift ist." which translates as, "All things are poison
and nothing is without poison; only the dose makes a thing not a poison." This is often
condensed that: "The dose makes the poison".2
The relationship between the dose of the chemical and the effects produced in
the organism is called the Dose- Response- Relationship. The relationship between
dose and its effects on the exposed organism is of great significance in toxicology.
The major criterion regarding the toxicity of a chemical is the dose, i.e. the amount of
exposure to the subject. Almost all substances are toxic under the right conditions.
The term LD50 refers to the dose of a toxic substance that kills 50 percent of a test
population. As the dose of a chemical is increased, the response (proportion of a
population showing a specified change) or effect (actual magnitude of the change in
the parameter) also increases.2
1.1.2 FACTORS AFFECTING TOXICITY
Toxicity of a substance can be affected by different factors,
 Pathway of administration (whether the toxin is applied to the skin, ingested,
inhaled, injected)
 Time of exposure (a brief encounter or long term),
 Number of exposures (a single dose or multiple doses over time),
 Physical form of the toxin (solid, liquid, gas),
 Genetic makeup of an individual,
 Individual's overall health and many others. 1
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1.1.3 SUB DISCIPLINES OF TOXICOLOGY
Type of toxicology
 Analytical toxicology
 Behavioral toxicology
 Carcinogenesis
 Clinical toxicology
 Information toxicology
 Developmental toxicology
 Drug toxicology
 Mutagenesis
 Pesticide toxicology
 Food toxicology
 Pre Clinical Toxicology
 Toxicogenomics
 Aquatic Toxicology
 Environmental Toxicology
 Forensic Toxicology
 Systemic Toxicology
Type of organ specific toxicology
 Dermatoxicology
 Hepatotoxicology
 Neurotoxicology
 Occupational toxicology.
 Ocular toxicology
 Renal Toxicology
 Pulmonary toxicology
 Cardiac Toxicology
 Reproductive toxicology
 Ototoxicology
 Immunotoxicology
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 Genetic toxicology2
1.1.4 TOXICOLOGY IS OFTEN SUB DIVIDED ON THE BASIS OF
EXPOSURE DURATION
Acute toxicity
In acute toxicity Effects are observed within a short time of exposure to the
chemical. This exposure may be a single dose, or a short continuous exposure, or
multiple doses administered over 24 hours or less. Acute toxicity looks at lethal
effects following oral, dermal or inhalation exposure.
Sub acute (sub chronic) toxicity
In sub acute toxicity Adverse effects are observed following repeated daily
exposure to a chemical, or exposure for a significant part of an organism's lifespan
(usually not exceeding 10%)
Chronic toxicity
Adverse effects are observed following repeated exposure to a chemical
during a substantial fraction of an organism's lifespan (usually more than 50%) or
some time up to the full span of the animal life.
1.2 TOXICITY TESTING
Toxicity can be measured by observing its effects on the target (organism,
organ, tissue or cell). Because individuals typically have different levels of responses
to the same dose of a toxin, a population-level measure of toxicity is often used which
relates the probabilities of an outcome for a given individual in a population. One
such measure is the LD50 (lethal dose 50). This means dose that kill 50% of mortality
in a population. When such data does not exist, estimates are made by comparison to
known similar toxic things, or to similar exposures in similar organisms. Then "safety
factors" are added to account for uncertainties in data and evaluation processes. For
example, if a dose of toxin is safe for a laboratory rat, one might assume that one
tenth that dose would be safe for a human, allowing a safety factor of 10 to allow for
interspecies differences between two mammals. If the data are from fish, one might
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use a factor of 100 to account for the greater difference between two chordate classes
(fish and mammals). Similarly, an extra protection factor may be used for individuals
believed to be more susceptible to toxic effects such as in pregnancy or with certain
diseases. Or, a newly synthesized and previously unstudied chemical that is believed
to be very similar in effect to another compound could be assigned an additional
protection factor of 10 to account for possible differences in effects that are probably
much smaller. Obviously, this approach is very approximate; but such protection
factors are deliberately very conservative and the method has been found to be useful
in a deep variety of applications.
It is more difficult to determine the toxicity of chemical mixtures than a pure
chemical, because each component displays its own toxicity, and components may
interact to produce enhanced or diminished effects. Common mixtures include
gasoline, tobacco smoking, and industrial waste. Even more complex are situations
with more than one type of toxic entity, such as the discharge from a malfunctioning
sewage treatment plant, with both chemical and biological agents1
LD50 (median lethal oral dose)
It is a statistically derived single dose of a substance that can be expected to
cause death in 50 per cent of animals when administered by the oral route. The LD50
value is expressed in terms of weight of test substance per unit weight of test animal
(mg/kg).
TYPES OF TOXICITY STUDIES
 Acute toxicity studies
 Sub acute toxicity studies
 Sub chronic toxicity studies
 Chronic toxicity studies
 Neurotoxicity studies
 Carcenogencity studies
 Genotoxicity studies
 Developmental and reproductive toxicity studies.
1.2.1 ACUTE TOXICITY STUDIES
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Objectives of acute toxicity studies
1. The objectives of acute toxicity testing are to define the “Intrinsic toxicity of
the chemical or drugs” to assess the susceptible, to identify target organs, to
provide information for risk assessment after exposure to chemical.
2. To provide information for the design and selection of dose level for
prolonged studies.
3. The acute toxicity data are essential in the classification, labeling and
transportation of chemical.
4. Acute toxicity studies are frequently designed to express the potency of
toxicant in terms of median lethal dose (MLD50)
5. Many acute toxicity studies have been conducted to determine the LD50 of the
chemical or drug.
6. A well designed acute toxicity studies should include consideration of both
lethal and non lethal parameters.
7. To discover and report any adverse health effect that could be related to the
chemical under study.
8. Acute toxicity studies are carried out by different manners like
 Oral acute testing
 Dermal acute toxicity testing
 Inhalation toxicity studies
Single Dose Oral Toxicity in rats/LD50 in rats
Animal model studied:
mice, n=10
Study duration : 14 days
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Data obtained from acute dose studies that are useful in the design of subsequent
studies
1. LD 50
2. Mortality
3. All animals survived the 2000mg/kg oral dose.
4. Body Weights
5. Body weight changes were normal in 7/10 animals. Three females lost weight
during the second week of the study.
6. Systemic Observations.
7. Physical signs included diarrhea, soiling of the anogenital area and wetness of
the mouth and anogenital area.
8. Necropsy Findings
9. Necropsy results were normal in all animals.3
1.2.2 SUB – ACUTE TOXICITY STUDIES
Repeated dose toxicity studies are conducted to screen for potential adverse
effects of a chemical using laboratory animals as surrogates for a target species, most
often the human. Repeated – dose studies may be of varying duration, generally 1 – 4
weeks for short term studies, 3 months for sub chronic studies and 6 – 12 months for
chronic studies. Procedures are done under OECD 407 guidelines
Sub-Acute Oral Toxicity Studies
Sub-acute oral toxicity study was designed and conducted to determine the
toxicity profile of Forslean when administered daily for 28 days in Sprague Dawley
rats. Test material suspended in 0.1% aqueous CMC was administered to the animals
at various dose levels. Hematological and biochemical analyses were carried out at
the end of experimentation.4
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Objectives of sub acute studies
 Determine adverse effects of the test compound at dose low enough to allow
survival of most animals as opposed to acutely toxic doses.
 Determine adverse effect over a longer exposure period than used in acute
studies.
 Determine dose – response for adverse effects following repeated dosing and
identify the NOAEL.
 Identify organs affected by exposure to test material (organ)
 Provide initial data for comparative risk assessment.
Data obtained from sub – acute dose studies that are useful in the design of
subsequent studies
 Palatability of test material
 Body weight response
 Physical observation
 Behavioral changes
 Clinical pathology
 Toxic kinetics
 Gross necropsy
 Histopathology
 Identification of target organs
 Dose response
 Isolated organ weight
1.2.3 SUB-CHRONIC TOXICITY STUDIES
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Sub chronic studies are designed to examine the adverse effect resulting from
respected exposure over a portion of the average life span of an experimental animal.
Properly designed gives valuable information on the cumulative toxicity of a
substance target organs and physiological, metabolic tolerance of a compound at low
dose (relatively to acute toxicity testing dose level) prolonged exposure. With the help
of this method various parameters, including histopathologic evaluation a wide
variety of ADR are detected. Result of this study provides information for selecting
dose level for chronic, reproductive and carcinogenicity. Sub chronic studies data
sufficient to for diet the benzoid long term, low dose, exposure of a particular
compound. Even though acute data indicated that the compound is practically non-
toxic but it may toxic from prolonged exposure even at low dose level. This toxic
effect may due to cumulation, changes in enzyme level and disruption of
physiological and biochemical hemostasis. Therefore sub chronic studies are essential
for all new chemical. The exposure period in sub chronic studies may vary, depending
upon the object of study, the species selected for study and the route of administration
employed. A general sub chronic study doesn’t exceed 10% of the animal life span.
Sub chronic toxicity studies are 13 to 26 weeks in duration. The animals are
dosed daily by the same route that the substance would normally be administered to
humans. They are then observed for any toxicity, as well as changes in body weight or
food consumption. At the end of the dosing regimen, the animals are euthanized and
their tissues evaluated for evidence of toxicity.5
1.2.4 CHRONIC TOXICITY STUDIES
Chronic studies are designed for long term toxicity of toxicants or toxins.
Duration of study will be 6 months to one year.
Chronic toxicity studies are designed to
 Examine, biological nature of toxic effects, from low dosages, at the cellular
level, measuring parameters that cannot usually be obtained in acute studies
because of the high dosage administered and rapidity of onset of toxic signs
and symptoms.
 Ascertain variations in species responses to repeated exposure to the agent.
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 Assess possible cumulative effects of the repeated exposure as body burdens
of agent and or bio transformation products are acquired with time.
 Determine nature of macroscopic and microscopic organs or tissue damage as
it develops hopefully I relation to the level and duration of exposure.
 Identify the approximate dosage at which the altered physiological,
biochemical and morphological changes might occur.
 Predict long range adverse health effects in the species arising from repeated
or chronic exposure to the particular agent.5
Parameters measured during studies
1. All animals committed to study must be daily observed.
2. One measurement of particular use in extended chronic studies, is the
survival time of the control and toxicant treated animals, presenting the
data in a plot of % survival time against time
3. Simple and most revealing end points are the body weight of animal,
measured every 2 or 3 days (twice weekly) throughout the duration of the
study.
4. Weigh isolated organs from animals. Their weight should relate to the
body weight of the animal.
5. Assessment of animal behavior, neurological function, hepatic and renal
function etc can be carried out periodically without the destruction of
valuable animals.
6. In chronic studies, routine clinical examinations should be conducted
periodically on control animal to provide a baseline of changes with age
and on the treated animals to ascertain whether or not exposure to the
toxicant can elicit any age related and dose dependent changes in organ
function.
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Duration of studies
Chronic studies regardless of the species used were of 2 years duration, this
time interval being based on the approximate life span of rodent. Chronic studies on
non rodent are of 1 year duration.5
1.2.5 NEUROTOXICITY STUDIES
Neuro or behavioral toxicities are complex having multiple dimensions and
behavioral domains. These are motoric, sensory and cognitive domains, each of which
can range from simple to highly complex levels of function. First clues of toxicity to
humans may be subjective disturbances such as nervousness or personality changes
other signs such as tremor or akenasi etc.
In past the neurotoxicity was thought to be neuropathy involving
neuropathological lesions or neurological dysfunction. Now it was clear that along
with neuropathy there are many other signs of nervous system toxicity (e.g. loss of
motor co-ordination, sensory deficits, learning and memory dysfunctions) that may
not be reflected in neuropathy or other types of studies.6
Neurotoxicity studies are designed to
 To identify whether the nervous system is permanently or reversibly affected
by the chemical tested;
 Contribute to the characterization of the nervous system alterations associated
with exposure to the chemical, and to understanding the underlying
mechanism.
 Determine dose-and time-response relationships in order to estimate a no-
observed adverse-effect level (which can be used to establish safety criteria for
the chemical).6
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Data obtained from neurotoxicity studies
 Body weight/body weight changes including body weight at kill
 Food consumption and water consumption,
 Toxic response data by sex and dose level, including signs of toxicity or
mortality;
 Nature, severity and duration (time of onset and subsequent course) of the
detailed clinical observations (whether reversible or not)
 A detailed description of all functional test results for sensory reactivity to
stimuli of different modalities (e.g., auditory, visual and proprioceptive); for
assessment of limb grip strength; for motor activity assessment (including
details of automated devices for detecting activity);
 Necropsy findings;
 A detailed description of all neurobehavioral, neuropathological, and
neurochemical or electrophysiological findings.
 Absorption and metabolism data, if available.
 Statistical treatment of results, where appropriate.
Duration of study
In neurotoxicity studies the animals are dosed with the test substance daily,
seven days each week, for a period of at least 28 days. Neurotoxicity studies are
combined with other toxicity studies also6.
1.3 TOXICANTS AND TOXINS
Toxicology deals with toxins and toxicants. A toxicant is any chemical that can injure
or kill humans, animals, or plants; a poison. The term “toxicant” is used when talking
about toxic substances that are produced by or are a by-product of human-made
activities. Where as toxin is any poisonous substance of microbial (bacteria or other
tiny plants or animals), vegetable, or synthetic chemical origin that reacts with
specific cellular components to kill cells, alter growth or kill the organisms.2
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Various toxicants and toxins are:
 Food bourne toxicants
 solvents and industrial toxicants
 crop  protection chemicals
 metals
 ionizing radiations
 plant and animal toxins1
From these we are dealing with metal toxicants.
1.3.1 METAL TOXICANTS
Metals are elements generally characterized by ductility, luster, electropositive
nature and having a property of conducting heat and electricity. But more than that
metal posses a variety of physiological effects. . Scarcity of some metal ions can lead
to disease. Well-known examples include pernicious anemia resulting from iron
deficiency, growth retardation arising from insufficient dietary zinc, and heart disease
in infants owing to copper deficiency.1
Metals also played an important role in medicinal system also. The use of
metals in medicine traces back to antiquity with various elements, such as arsenic,
gold and iron, being used to treat different ailments. In more modern times, perhaps
the first metal-based drug to find wide use was an arsenical, Salvarsan, developed by
Paul Ehrlich, used in the treatment of Syphilis. Diseases such as anemia (iron), asthma
(gold and magnesium), bipolar disorder (lithium), diabetes (vanadium), rheumatoid
arthritis (gold), stroke (magnesium), tropical diseases (antimony and rhodium) and
ulcers (bismuth) can all be treated by metal-based drugs. Most successful metal
containing drug is cisplatin having a platinum center used in cancer chemotherapy. In
most of the complimentary and alternative medicines like ayurveda and siddha also
uses metal containing drugs for various diseases.7
The main problem involved in metal based drug therapy is toxicity. Clearly
there is a subtle balance between therapeutic benefit on the one hand and deleterious
side effects on the other. Essential elements may be toxic at a dose that overwhelms
homeostatic controls on absorption and excretion. The variety of physiological effects
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that metals can have is also the reason that adverse effect can often demonstrated in
most organs: neurotoxicity, hepatotoxicity reproductive toxicity and nephrotoxicity.
In this study iron containing ayurvedic medicines is taken as a metal toxicants.
1.4 IRON
Iron is silver-white solid metal found mainly in combination with other
elements as oxides, carbonates, sulfides, and silicates. Iron represents approximately
35 and 45 mg/kg of body weight in adult women and men, respectively. The majority
of total body iron, about 60±70%, is present in hemoglobin in circulating
erythrocytes. Another 10% of essential body iron is present in the forms of
myoglobins, cyto-chromes, and iron-containing enzymes, amounting to no more than
4±8 mg of iron. In healthy individual, the remaining 20±30% of surplus iron is stored
as ferritins and hemosiderins in hepatocytes and reticuloendothelial macrophages.
Being one of the most abundant metals in the human body, iron plays important roles
in cellular processes such as the synthesis of DNA, RNA, and proteins; electron
transport; cellular respiration; cell proliferation and differentiation; and regulation of
gene expression.8
Iron is also the key component of many cellular enzymes, such as oxidases,
catalases, peroxidases, cytochromes, ribonucleotide reductases, aconitases, and nitric
oxide synthases. Most importantly, iron plays a crucial role in maintaining cellular
iron homeostasis by regulating gene expression at the posttranscriptional level.
Globally iron deficiency is the most common cause of anemia, there was a decrease in
mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular
hemoglobin concentration. Various iron salts are used for the treatment iron
deficiency anemia.8
Uses of iron
 Treatment of iron deficiency anemia
 Supplemental intake of iron during pregnancy
 Multivitamin preparations
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1.4.1 ABSORPTION OF IRON
Absorption of both heme and non heme iron occur predominantly in the
proximal small intestine, specifically in the crypt cells of the duodenum and jejunum
Fig .Pathways of heme and non heme iron uptake and transport in the intestine8
it was well known that under normal circumstances only a small proportion of any
iron compound given by mouth is absorbed. As an explanation of this small
absorption McCANCE and WIDDOWSEN have suggested that the absorption of iron
is conditioned mainly by the relative concentration of free ionized iron in the lumen of
the intestine .It was reported in a study of absorption of iron compounds from the
small intestine of rats as absorption was found to be increased when the iron salts
were added either an organic reducing agent (ascorbicacid, cystein, glutathione,
formaldehyde sulphoxylate) or some organic acid. Especially plant acids (citric,
tartaric, succinic, malic acid), lactic acid, pyruvic acid and some amino acids
(glutamic, aspartic acid) were active in this respect. From these studies and
explanations we can elaborate some statements.8-9
 Iron is absorbed as ferrous ion only.
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 Iron can persist in the ionized ferrous form only in acid medium.
 The normal PH of the small intestine is about 6. At this PH, almost all the iron
is transformed in the complex or ferric form, neither of which is absorbed to a
measurable degree. This explains the poor absorption of iron from a simple
solution introduced into the gut.
 The intestine tends to reestablish its neutral reaction if acids are introduced
together with the iron salt. Hydrochloric and phosphoric acid are very quickly
absorbed. For this reason these acids cannot keep the PH inside the gut down
for a long time and therefore do not promote iron absorption to a measurable
degree.
 The organic acids and reducing agents (all acid in character) that promote iron
absorption appear to do so by keeping the PH of the intestine down for a
longer time. As soon as the intestinal content becomes neutral, all the iron is
transformed into the complex or ferric form and the absorption stops.9
1.4.2 TOXICITY OF IRON
Iron levels must be well maintained within cells, because excess iron is highly
toxic. The deleterious effect of iron is due to the generation of reactive oxygen species
by Fenton reaction.
Fe+3 + .O2 Fe+2 + O2;   Fe+2 + H2O2 Fe+3 + .OH + OH-
Fenton reaction have the potency to generate highly reactive oxygen species, such as
hydroxyl(OH-) and superoxide radicals(.O2) which are highly toxic and they react
rapidly with high affinity with every molecule found in living cells. Due to this
reaction of free radicals there will be DNA damage; impaired synthesis of proteins,
membrane lipids and carbohydrates; induction of proteases; and altered cell
proliferation.
Free iron can also react directly with unsaturated fatty acid and induce lipid hydro
peroxides to form alkoxyl or peroxyl radicals thus impair cellular integrity and cause
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cell death. This deleterious potential of iron might play a role in neurodegenerative
disorders such as Parkinson’s or Alzheimer’s diseases; hepatic and nephritic disorders
and carcinogenesis.8
 Toxic dose: 10-20 mg elemental iron
 Fatal dose: 40-1600 mg/kg of elemental iron
1.4.3 NEUROTOXICITY BY IRON
As in other organs, the brain needs iron for metabolic processes and iron
deficiency or excess result into pathological states. Some physiological roles of iron
within the brain are in embryonic neuronal development, in myelin formation, in
synthesis and metabolism of neurotransmitters, in oxidative phosphorylation and ATP
synthesis. Brain contains the highest quantity of iron other than that of liver 60 mg of
iron is distributed through out the brain.1
Fig: 1.1 A schematic diagram of the changes in iron and iron management proteins in
neurodegenerative disorders. 10
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Disruption of iron regulatory mechanisms and iron accumulation may
contribute to development and progression of neurodegenerative disorders such as AD
and PD. In Alzheimer’s diseased humans brain is characterized by the accumulation
of iron within senile plaques and neurofibrillary tangles, and also by lowered
expression of transferring receptor. As a consequence, these brains are subject to high
levels of oxidative stress.11,12
As for PD, dopaminergic cell loss and disease progression are accompanied by
the accumulation of high iron concentrations, that are particularly associated with
aggregation of _-synuclein (especially the mutated form found in familial PD) within
Lewy bodies.
Fig: 1.2 Representation of iron-induced cell death in neuronal cells10
Many other neurodegenerative diseases, such as Huntington’s disease, Frederic’s
ataxia, amyotrophic lateral sclerosis, and prion disease shows increased accumulation
of iron in brain. So proper neurotoxicity studies should be conducted for iron based
preparations.10
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1.4.4 HEPATOTOXICITY OF IRON
Iron accumulates in liver at large quantities, Due to the generation of
destructive free radicals via fenton reaction there will be detritions of   liver cells
occurs. Free iron is delivered by way of the portal vein to the liver causing damage
and iron deposition in these areas. The result in severe cases is periportal liver damage
(opposed to the centrilobular necrosis seen with APAP).8
In the liver, hereditary hemochromatosis has been found associated
with an increased risk of hepatocellular carcinoma. Several mechanisms have been
implicated in promoting carcinogenesis. Iron enhances cellular proliferation genes.
Moreover, ROS formation may induce chromosome strand breaks and mutations. Not
to be neglected, iron may suppress the immune system also.13
In a study it was reported as iron overload reduced body growth with
the increase of liver weight. This might be why marked deposition of iron in the liver
injured the hepatic cells and disturbed liver function, i.e. levels of activity of hepatic
enzymes such as LD and ALP were lowered in iron-overloaded animals.
Hepatocellular injury due to the superoxide radical, H2O2, and the hydroxyl radical
produced with the deposited iron might stimulate the hepatocellular development and
increase the liver weight. The reduced function of the liver could reduce body growth.
Iron overload in the liver is known to reduce bone mass with liver cirrhotic change in
liver iron overload syndromes. So liver cells are highly suspicious for toxicity by iron
containing preparation.8,13
1.4.5 NEPHROTOXICITY OF IRON
Several diseases are associated with accumulation of iron in the kidney, and
this is generally thought to be deleterious to renal function. In nephrotic kidney
diseases that are associated with increased permeability of the glomerular filter,
increased Tf(trans ferrin) reabsorption causes iron accumulation in PT lysosomes and
this is associated with kidney injury. Iron-induced ROS formation in PT cells could
well contribute to the progression of protein uric chronic kidney diseases.14
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In a study it was reported that Iron overload into the kidney lowered renal
function, i.e. the plasma levels of BUN and CRE were elevated, the plasma levels of
Ca and iP were reduced, and vacuolization, swelling, desquamation, and necrosis in
the proximal tubular epithelial cells of the kidney were observed in iron-overloaded
rats. The urinary discharge of Ca might be increased by the disturbance in
reabsorption of urinary Ca from the proximal tubular epithelial cells affected by the
hydroxyl radical produced with iron overload.13
Another study shows that an iron-chelate of nitrilotriacetate, Fe-NTA induces
acute and sub-acute renal injury in animals.Repeated intraperitoneal administration of
ferric nitrilotriacetate (Fe-NTA) was reported to cause high degree of renal adeno-
carcinoma in rats and mice. So iron overload of the kidney may well be associated
with an increased risk of renal carcinoma.15
1.5 METAL CONTAINING AYURVEDIC MEDICINES
Ayurvedic medicine (also called Ayurveda) is one of the world’s oldest
medical systems. It originated in India and has evolved there over thousands of years.
The term “Ayurveda” combines the Sanskrit words ayur (life) and veda (science or
knowledge). Thus, Ayurveda means “the science of life”. Ayurvedic medicines have
developed into highly sophisticated systems of diagnosis and treatment over the
centuries. Ayurvedic treatment goals include eliminating impurities, reducing
symptoms, increasing resistance to disease, and reducing worry and increasing
harmony in the patient’s life. In recent times public interest was shifted towards
ayurvedic medicines due to its less side effects.16
Ayurvedic medicine holds the following beliefs about the three doshas: vata,
pitta, and kapha.
The vata dosha combines the elements ether and air. It is considered the most
powerful dosha because it controls very basic body processes such as cell division,
the heart, breathing, discharge of waste, and the mind .
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The pitta dosha represents the elements fire and water. Pitta controls hormones and
the digestive system. A person with a pitta imbalance may experience negative
emotions such as anger and may have physical symptoms such as heartburn within 2
or 3 hours of eating .
The kapha dosha combines the elements water and earth. Kapha helps to maintain
strength and immunity and to control growth. An imbalance of the kapha dosha may
cause nausea immediately after eating 16
Ayurvedic medicines are divided into 2 major types: herbal-only and rasa
shastra.siddha nagarjuna considered to be the father of Indian alchemy or ‘vedic
chemistry’ and rasa sastra.
1.5.1 RASA SHASTRA
Rasa-shastra is a branch of Ayurveda, which deals with Rasa, Uparasa, Lohas
(I.e. Minerals & Metals), Yantras, Methods of Shodhana, process of Satvapatana,
Druti, Process of Bhasma preparation etc.”17
Rasa sastra includes the extraction of metals from their mineral,their
purification and conversion in to digestible metallic bhasmas.the word rasa denote
numerous things including mercury. At the time of 15th century the technology for the
preparation of bhasmas has been developed and use of other metals like zinc, tin and
antimony also begun.
The process of manufacturing metal containing bhasmas include
1) Satvapatna(metal extraction)
2) Bhasmikarana (conversion to non toxic chemical form)
3) Other Processes (conversion to metallic chemicals by using sublimation and
distillation)
The processing of minerals, metals and gems can be classified in to the following
steps
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1. Selection and control of raw materials
2. Sodhana or purification(grinding with various drugs to remove their toxins)
3. Marana or conversion to non toxic fine powdered form
4. Mardan or bhavana (preparation of  intermediate paste)
5. Jarana or putapak(medicines are properly  made by incineration in putas).17,18
The various types of bhasmas in Indian ayurvedic system include Abhraka
Bhasma, Vaikrant Bhasma, Swarnamakshika Bhasma, KasisBhasma, Svarna
Bhasma, Rajat Bhasma, Tamra Bhasma, Loha Bhasma, Mandur Bhasma, Naga
Bhasma, Vanga Bhasma,Yashad Bhasma, Trivanga Bhasma, Pittal,Kamsya and
Varthaloha Bhasma, Shankha Bhasma, Shukti Bhasma, KapardikaBhasma,
Godanti Bhasma, Praval Bhasma, Mrigashringa Bhasma,
MayurpicchaBhasma, Kukkutand twaka Bhasma, Hiraka Bhasma, Manikya
Bhasma.
Ayurvedic medications have the potential to be toxic. Many materials used in
them have not been thoroughly studied in either Western or Indian research.
According to a new study, one-fifth of Ayurvedic medicines made in  USA and India
and sold in USA through the Internet contain more than permissible levels of toxic
metals includes mercury, zinc ,lead and arsenic. The study recently appeared in the
Journal of American Medical Association (JAMA).19
Some cases are also reported about the lead and mercury poisoning from Indian
folk remedies. A study reported 3 cases of lead poisoning in India by ayurvedic metal
containing medicines Also a study reported that Iron overload occurs in 1/200 to
1/400 of people. In the average primary care practice, this figure translates to about 4
to 8 patients with iron overload.16 Toxicological profile for  most of metal containing
ayurvedic medicines are sorely missing so proper toxicological studies should be
conducted with special emphasis on neurotoxicity ,nephrotoxicty and hepatotoxicity.5
In this investigation we are dealing with the toxicity of two iron containing bhasmas
they are swarna makshika bhasma and kasisa bhasma although number of iron bearing
Ayurvedic medicines are available but we restrict to these bhasma only because
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 No  toxicological profile was available for these bhasmas
 Large quantities of these bhasmas are imported to western countries like
U.S.A and U.K
 They are not only effective in treatment of anemia but also used in therapy of
multiple diseases,
 These bhasmas are readily available in market and cost effective.
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1.6DRUG PROFILE
1.6.1 SWARNA MAKSHIKA BHASMA (S.M.B)
Chemical Nature
X-ray crystallography shows that Raw Swarna makshika bhasma contains
CuFeS2 also known as chelco pyrite. Final product of S.M.B contains Fe2O3, FeS2,
CuS and SiO2.
Particle size: 1-2 microns.
PREPRATION
Sodhana
At first raw swarna makshika was powdered with help of iron mortar and
pestle. Powdered swarna makshika was subjected to intense heat in a dry iron pan
with frequent addition of lemon juice till the liberation of  sulphur fumes stopped and
it turned red. The process was completed in 3 days and the final product called
purified swarna makshika.
Marana
Equal amounts of purified swarna makshika and purified sulphur were
triturated with lemon juice till a homogeneous paste was formed .after triturating
,small pellets of uniform size and thickness were prepared and dried in sunlight
.pellets were kept inside a sharava (shallow earthen disc) and another sharava was
inserted over it. The joint between the two disc was sealed.the properly sealed and
dried samputa was subjected to puta system of heating with 3.5 kg cow dung cakes
the process is repeated using purified sulphur in equal proportion. Bhasma of desired
quantity was obtained in 13 putas.
Dosage: 125 mg-250mg twice daily (9mg/kg).
Uses: When there is severe deficiency of iron in the body this drug is sometimes
preferred. It is also used for anemia, insomnia, convulsions, poor digestion and skin
diseases.20
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1.6.2 KASIS BHASMA (K.B)
Kaseesa (Green vitriol), is the ancient drug widely used in therapeutics of Ayurveda.
Fig: 1.3 Kasis bhasma
It is brownish black, odorless and tasteless
Chemical nature
Raw kasis bhasma is FeSO4 7H2O. but final product consist of ferrous sulphate
, ferric oxide and various metals like copper, nickel cadmium, lead etc.
PREPRATION
Sodhana
Raw kasis was taken in an end runner and a fine powder is made. Bhringaraja
swarasa was added little by little till the whole powder becomes wet. It is grinded for
3 hours till the liquid added dries up and this is considered as one bhavana. The above
process was repeated for 3 times,the obtained kasis is dried and used. Duration for
sodhana is 9 hours.
Fig: 1.4 Purified kasis
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Marana
Shuddha Kaseesa was made in to fine powder with the help of an end runner,
Nimbu swarasa was added little by little till the powdered drug gets fully immersed
and grinded. This is made in to fine paste and pellets (chakrika) were prepared and
dried. After drying these chakrika was kept in sarava, sarava samputa was prepared by
sealing the edges of sarava with the help of a cloth smeared with multani mitti and
dried. After drying, it was subjected to puta with abovesaid upalas. After swangasitala
(self cooling) the sarava samputa were taken out and product of Kaseesa was
collected and weighed. The same procedure was repeated for four times and before
each puta Nimbu swarasa Bhavana (trituration) was given.
Dosage: 125mg- 250 mg daily (4.5mg/kg).
Uses: Haematinic & alterrative. Used in anemia, enlargement of liver and spleen,
abdominal diseases, cough & general weakness.21
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LITERATURE REVIEW
Scientific literature review is the main basis for the planning of any scientific
work and due to the same reasons here the review of literature regarding “Toxicity
study of two iron containing bhasmas swarnamakshika bhasma and kasisa bhasma”
 R.B Saper et al. JAMA. 2008 August. reported that Lead, Mercury, and
Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the
Internet
The author reported that from One hundred ninety-three of the 230 requested
medicines 20.7% contains detectable amount of heavy metal. Lead was the most
commonly found metal, followed by mercury and arsenic. The prevalence of metal-
containing products did not differ significantly between US- and Indian-manufactured
products. The median lead concentration in Indian manufactured vs US-manufactured
lead-containing products was similar. Mercury was present in greater concentrations
in Indian-manufactured products. Rasa shastra compared with non– rasa shastra
medicines were more than twice as likely to contain metals. Rasa shastra
metalcontaining medicines had higher lead and mercury median concentrations than
non–rasa shastra metal-containing medicines.
 P. K Sarkar et al. Indian journal of experimental biology, 2009, reported
toxicity and recovery study of two iron containg bhasmas
The author reported that toxicity and recovery study of two iron containing
bhasmas ,lauha bhasma and mandura bhasma(55mg/kg) for 60 days in Charles foster
rats shows an increase in serum alkaline phosphtase level in mandura bhasma
recovery group, where as the elevation is non significant in case of lauha bhasma
recovery group.in liver autopsy moderate fatty degenerative changes, diffused
necrosis, periportal necrosis, central vein congestion and sinusoidal dilatation is seen
lauha bhasma treated group while in case of mandura bhasma treated group also
shows mild fatty changes and sinusoidal dilatations.in case of kidney a mild decrease
in serum urea level in both the test drug treated group. A mild increase in the serum
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creatinine level also shown in both the treated group when compared with control but
histopathological observation of control and drug treated rats indicate absence of any
gross pathological lesion in kidney
 A.V singh et al, Indian Journal of Clinical Biochemistry, 2003, reported
toxicology and free radicals scavenging property of tamra bhasma
The author reported that tamra bhasma at doses of 20mg/100g showed
necrosis and inflammation of kidney but serum urea and creatinine does not shows
significant changes. liver showed some histopathological changes at the dose of
20mg/100g body weight. But biochemical analysis did not showed any change in the
activity of serum GOT, GPT,alkaline phosphatase.
 Singh et al. Journal of Herbal Medicine and Toxicology 4 (1), 2010,
reported acute and subchronic toxicity study of calcium based ayurvedic
‘bhasmas’ and a ‘pishti’ prepared from marine animals.
The author highlights experimental results on toxicity study of calcium
basedfour ayurvedic bhasmas and a pishti prepared from marine -sourced animals
viz.Shankha bhasma, Kapardika bhasma, Muktashukti bhasma, Pravala bhasma,
andPravala pishti respectively. Mice administered above mentioned drugs did not
show any abnormalbehaviour and no mortality was observed during 72 hrs in any
experimental group.The levels of glucose, cholesterol, alkaline phosphatase,
glutamate oxaloacetate transeminase, glutamate pyruvate transeminase, blood urea
nitrogen, creatinine, total protein and albumin were not altered significantly in four
bhasmas and a pishti treated rats compared to control rats. Serum electrolyte
concentration viz. sodium, potassium, chloride and calcium showed no significant
change, when compared to the control rats. The levels of haemoglobin and WBC
count were not changed significantly. There was no sign of haemopoetic, hepatic or
renal toxicity. Histopathological observation of control and drug treated rats indicate
absence of any gross pathological lesion in liver, stomach and kidney. All animals
were found healthy during entire study period and devoid of deleterious effects. All
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four bhasmas and a pishti taken for the study did not showed any sign(s) of toxic
manifestation.
 NAGARAJU.V et al. Ancient Science of Life, Vol. IV No.1, July 1984,
reported Toxicity studies on vanga bhasma
The author reported dose-effect relation of Vanga bhasma on Digestive
system (G.I. T., Liver and Pancreas) has been presented. But for local irritation, no
significant toxicity attributable to Vanga bhasma has been observed even in eight
time’s higher dose than therapeutic dose, on exposure to the drug for ten days.
 DAWOOD SHARIEF, S., et al. Journal of Cell and Tissue Research Vol.
9(2),2009, reported histopathological studies of the effect of nagaparpam, a
zinc based drug of siddha medicine, in rats
The author reported that in 15 day treatment, liver and kidney had normal
histology with no marked changes in the tissue architecture. in 30 day study, the
kidney tissues remained normal while the liver tissues exhibited a few apoptotic cells
with mild focal and lobular inflammation. On 60 day treatment, liver showed mild
lobular inflammation and apoptotic cells were found in all doses. However brain,
kidney and testis remained normal even in higher doses. The results suggest that NP
does not show any toxicity in short term administration which is advocated in siddha
literature for all metal based drugs.
 P.V Balendu et al. International Journal of Toxicological and
Pharmacological Research 2010, reported Acute and Sub acute Toxicity
Study of Ayurvedic Formulation (AYFs) Used for Migraine Treatment
The author highlights Acute and Sub acute Toxicity of five classical
ayurvedic formulations (Narikela Lavana, Sootashekhara Rasa, SitopaladChurna,
Rason Vati and Godanti Mishran) has been employed as prophylactic remedy for
migraine was administrated in various doses ranging from 1.47 –6.48g/kg for mice
and 0.7 – 7.45 g/kg for rats Animals from high dose treatment group and satellite
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group of both the species showed decreased motor activity (reduced alertness, reduced
exploratory behavior). The effect lasted for approximately two hours post dose
administration and they responded comparably to control group in the functional test
on rotarod. It may be assumed that the AYFs at high dose may have mild CNS
depressant activity but pathological study of brain does not showed any signs of
toxicity. And it does not shows any biochemical and histopathological changes in
kidney and liver.
 K.J Thompson et al. Brain Research Bulletin, Vol. 55, 2001, reported Iron
and neurodegenerative disorders
The author reported that As a result of a loss in iron homeostasis, the brain
becomes vulnerable to iron-induced oxidative stress. Oxidative stress is a
confounding variable in understanding the cell death that may result directly from a
specific disease and is a contributing factor to the disease process. The underlying
pathogenic event in oxidative stress is cellular iron mismanagement.
 M.P Horowitz et al. J Alzheimer’s Dis. 2010, reported Mitochondrial Iron
Metabolism and Its Role in Neurodegeneration.
The author reported about the physiological role that mitochondria play in
cellular iron homeostasis and, in so doing, attempts to clarify how mitochondrial
dysfunction may initiate and/or contribute to iron dysregulation in the context of
neurodegenerative disease. And the ways in which iron is utilized therein, and how
mitochondria are integrated into the system of iron homeostasis in mammalian cells.
Author discuss about the dysregulation of iron in neurodegenerative diseases and
effect of iron chelation in such diseases.
 LIU ET AL. the Society for Experimental Biology and Medicine 2008,
reported Mercury in Traditional Medicines: Is Cinnabar Toxicologically
Similar to Common Mercurial’s?
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The author comments on natural mineral cinnabar used in traditional
medicines. Cinnabar is insoluble, has very low bioavailability and thus is poorly
absorbed from the gastrointestinal tract. Once absorbed into the blood, the mercury
disposition from cinnabar follows the pattern for inorganic mercury salts and
preferentially distributed to the kidneys, with a small portion to the brain. The heating,
overdose and the long-term use of cinnabar are major causes of mercury intoxication,
but at the therapeutic doses, the adverse effects cinnabar-containing traditional
medicines seem to be tolerable and reversible.
 Uchida et al./FEBS Letters 357 (1995) , reported Acute nephrotoxicity of a
carcinogenic iron chelate Selective inhibition of a proteolytic conversion of
e2u-globulin to the kidney fatty acid-binding protein
The author reported the mechanism of acute nephrotoxicity of an ironchelate
in vivo. Administration of a renal carcinogen ferric nitrilotriacetate (Fe-NTA) (15 mg
Fe/kg body weight, intraperitoneally) led to selective loss of a renal protein with an
apparent molecular mass of 17 kDa An immunochemical study using anti-a2u-
globulin polyclonal antibodies confirmed that a single injection of Fe-NTA led to a
decrease in k-FABP levels. However, a 19-kDa protein identical to the C~zuglobulin
progressively appeared in the kidney, suggesting that the proteolytic processing of
azu-globnlin in the renal proximal tubules was suppressed by the treatment with Fe-
NTA. By monitoring k-FABP and its precursor Ot2u-globulin , it was determined that
repeated exposure to Fe-NTA caused suppression of both proteolytic and endocytotic
activity of the kidney.
 Chandramouli R et al /J. Pharm. Sci. & Res. Vol.2 (12), 2010 reported
Designing Toxicological Evaluation of Ayurveda and Siddha Products to
Cater to Global Compliance – Current Practical and Regulatory Perspectives.
The author discusses on viable means to design, conduct and document studies
of ayurvedic products for all possible toxicological manifestations in GLP conditions
that can withstand global scrutiny and audit. It  explains how to plan the protocol,
choose the test systems, chalking out the observation routine, and conduct, acute, sub-
acute, sub-chronic, and chronic toxicity studies, with an additional emphasis on
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carcinogenicity, neurotoxicity, genotoxicity and developmental & reproductive
toxicity studies. Determining scientifically consistent toxicological profile of
ayurvedic drugs complying with current regulatory practices can be a fillip to their
prospects of wide spread acceptance.
 Tripathi et al. / International Journal of Engineering, Science and
Technology, Vol. 2, No. 8, 2010, reported Chemical phases of some of the
Ayurvedic heamatinic medicines
The author reported that Chemical phases of iron in some of the Ayurvedic
medicines are investigated through Mössbauer Spectroscopy and FTIR. In all the four
medicines studied, iron is found in oxide form, either Fe2O3 or Fe3O4 or both. The
size distribution of iron particles is different for different medicines. FTIR spectra are
characteristically different for different drugs. These oxide particles are dispersed in a
base probably consisting of ash of herbs or compound used as the medium for the
preparation of these medicines which might control the efficacy and concentration of
iron in these drugs.
 Dr. Devanathan.R et al. / Journal of Pharmacy Research 2011, reported
Standardization of Kaseesa  Bhasma: An Ayurvedic Medicine
The author reported that in analytical study of kasisa bhasma by the help of
AAS and flame photometer shows a marked improvement in the concentration of
Iron, in the final product as compared to the raw drug. Especially the concentration of
iron in the raw drug was 243.97 ppm, while in the purified sample it was 394.40 ppm
and in the final product it was increased to 885.40 ppm. An increase in number of
putas proportionately decreases the doshas (impurities) and subsequently increases
the therapeutic value of Kaseesa Bhasma.
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 s. mohapatra et al.international journal of ayurvedic research vol 1, 2010,
reported physicochemical characterization of ayurvedic bhasma (swarna
makshika bhasma): an approach to standardization
The author reported that the analytical study of S.M bhasma by the help of X
ray diffraction revealed that SM raw material contains CuFeS2 and SM bhama
contains Fe2)3, FeS2, CuS and SiO2.scanning electron microscope showed that SM
bhasma were uniformly arrange in agglomerates of size 1-2 microns compared to the
raw.
 Devanathan R et al. international journal of research in ayurveda and
pharmacy 2(1), 2011, reported concept of bhasmikarana
The author reported that preparation of bhasma is an elaborate process
involving sodhana and bhasmikaran, bhasmas are prepared by the process of marana
and putapaka method, the metals and minerals are converted in to micro fine form.
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CHAPTER 3
AIM AND SCOPE OF WORK
For centuries detoxified digestible metals (bhasmas) are used for the treatment
in ayurveda, this comes under rasasastra a branch of ayurveda. Rasasastra includes the
extraction of metals from their mineral, their purification and conversion in to
digestible metallic bhasmas. By this processes the metals are detoxified and converted
in to wonder substances.
Nowadays information’s about ayurvedic medicines are widely available in
internet and are exported largely to western countries. The prevalence of metals in
ayurvedic medicines sold via the Internet and exported from India is under scanner.
One-fifth of ayurvedic medicines made in India and sold in western countries through
the Internet contain more than permissible levels of toxic metals includes mercury,
zinc ,lead and arsenic. Although ayurvedic medicines are time tested for its efficacy
proper toxicological studies are sorely missing so at fundamental level the bhasma as
a medicine needs detailed scientific scrutiny about its toxicological profile and
physicochemical characteristics.
In this study we are dealing with Swarna makshika and kasisa bhasma .These
are two iron containing bhasmas widely used as haematinic and for iron deficiency
anemia.
 The aim of present study was to evaluate the toxicity profile of two iron
containing bhasmas swarna makshika and kasis bhasma with special emphasis
on Neurotoxicity, Nephrotoxicity and Hepatotoxicity.
Although number of iron bearing Ayurvedic medicines are available but we restrict to
these bhasma only because:
 No toxicological profile was available for these bhasmas.
 Large quantities of these bhasmas are imported to western countries like
U.S.A and U.K.
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 They are not only effective in treatment of anemia but also used in therapy of
multiple diseases.
 These bhasmas are readily available in market and cost effective.
CHAPTER – 4
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CHAPTER 4
PLAN OF WORK
PART 1: ACUTE TOXICOLOGICAL STUDIES
 Selection of animal species
 Housing and feeding conditions
 Preparation of animals
 Preparation of doses
 Administration of doses
 Observations
 Data collection and reporting.
PART 2: NEUROTOXICITY STUDY IN COMBINATION
WITH   REPEATED DOSE SYSTEMIC TOXICITY
(HEPATOTOXICITY AND   NEPHROTOXICITY) STUDY
 Selection of animal species
 Housing and feeding conditions
 Preparation of animals
 Preparation of doses
 Administration of doses
 Observations
 Data collection and reporting
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CHAPTER 5
MATERIALS AND METHODS
5.1 ACUTE TOXICOLOGICAL STUDIES
Acute toxicological studies are carried out according to OECD Guidelines
425. Description of method and materials which are done in these studies are
mentioned below.
5.1.1 SELECTION OF ANIMAL SPECIES
The preferred rodent species which are used in this study is swiss albino
mice. Normally female mice are used. This is because literature surveys of
conventional LD50 tests show that usually there is little difference in sensitivity
between sexes, but in those cases where differences are observed, females are
generally slightly more sensitive. Hence in this study, 17 female mice are used for
both bhasmas.
Healthy young adult mice’s of commonly used laboratory strains should be
employed. Females should be nulliparous and non-pregnant. At the commencement of
its dosing, each animal should be between 4 and 8 weeks old and its weight should
fall in an interval within ± 20 % of the mean initial weight of any previously dosed
animals.
5.1.2 HOUSING AND FEEDING CONDITIONS
The temperature in the experimental animal room should be 22°C (± 3°C).
Although the relative humidity should be at least 30 % and preferably not exceed 70
% other than during room cleaning, the aim should be 50-60%. Lighting should be
artificial, the sequence being 12 hours light and 12 hours dark. The animals are
housed individually. For feeding, food pellets are purchased from Kerala Agricultural
University, College of Veterinary and Animal Sciences Mannuthy, Thrissur used with
an unlimited supply of drinking water.
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5.1.3 PREPARATION OF ANIMALS
The animals are randomly selected, marked to permit individual identification
of both bhasma treating groups, and kept in their cages for at least 5 days prior to
dosing to allow for acclimatization to the laboratory conditions. As with other
sequential test designs, care must be taken to ensure that animals are available in the
appropriate size and age range for the entire study.
5.1.4 PREPARATION OF DOSES
In general, test substances should be administered in a constant volume over
the range of doses to be tested by varying the concentration of the dosing preparation.
i.e., at a constant concentration, may be more relevant to the subsequent risk
assessment of that substance, and is a requirement of some regulatory authorities. In
either case, the maximum dose volume for administration must not be exceeded. The
maximum volume of liquid that can be administered at one time depends on the size
of the test animal. In rodents, the volume should not normally exceed 1 ml/100g of
body weight; however in the case of aqueous solutions, 2 ml/100g body weight can be
considered. With respect to the formulation of the dosing preparations, the use of an
aqueous solution/suspension/emulsion is recommended wherever possible, followed
in order of preference by a solution/suspension/emulsion in oil (e.g. corn oil) and then
possibly solution in other vehicles. For vehicles other than water the toxicological
characteristics of the vehicle should be known. Doses must be prepared shortly prior
to administration unless the stability of the preparation over the period during which it
will be used is known and shown to be acceptable.
In this study, vehicle used is 3% gum acacia (3g in 100ml).was prepared prior
to the preparation of drug suspension, for 2000mg/kg dose, 2000mg of swarna
makshika bhasma and kasis bhasma was suspended in 10ml of 3% acacia separately
and for 5000mg/kg dose; 5000mg of swarna makshika bhasma and kasis bhasma was
suspended in 10 ml of 3% acacia separately shortly prior to the administration. Doses
are prepared in mortar and pestle.3
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5.1.5 PROCEDURE
Administration of Doses
The test substance is administered in a single dose by gavages using a stomach
tube or a suitable intubation cannula. In the unusual circumstance that a single dose is
not possible, the dose may be given in smaller fractions over a period not exceeding
24 hours. In these studies all the doses are given as a single dose.
Animals were fasted prior to dosing. With the mice, food but not water should
be withheld overnight. Following the period of fasting, the animals should be weighed
and the test substance administered. The fasted body weight of each animal is
determined and the dose is calculated according to the body weight. After the
substance has been administered, food may be withheld for 1-2 hours in mice. Where
a dose is administered in fractions over a period of time, it may be necessary to
provide the animals with food and water depending on the length of the period. 3
Limit test and Main Test
The limit test is primarily used in situations where the experimenter has
information indicating that the test material is likely to be nontoxic, i.e., having
toxicity below regulatory limit doses. Information about the toxicity of the test
material can be gained from knowledge about similar tested compounds or similar
tested mixtures or products, taking into consideration the identity and percentage of
components known to be of toxicological significance. In those situations where there
is little or no information about its toxicity, or in which the test material is expected to
be toxic, the main test should be performed. 22
Limit Test
Limit Test at 2000 mg/kg
Dose one animal each for the test dose of both test drugs. If the animal dies,
conduct the main test to determine the LD50. If both animals survive for each test
drug, dose four additional animals sequentially for both drugs so that a total of five
animals are tested for both test drugs. However, if three animals die, the limit test is
terminated and the main test is performed. The LD50 is greater than 2000 mg/kg if
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three or more animals survive. If an animal unexpectedly dies late in the study, and
there are other survivors, it is appropriate to stop dosing and observe all animals to see
if other animals will also die during a similar observation period. Late deaths should
be counted the same as other deaths. The results are evaluated as follows (O=survival,
X=death).
The LD50 is less than the test dose (200 mg/kg) when three or more animals die.
O X O X X
O O X X X
O X X O X
O X X X X
If a third animal dies, conduct the main test.
Test five animals. The LD50 is greater than the test dose (2000 mg/kg) when three or
more animals survive.3
O O O O O
O O O X O
O O O O X
O O O X X
O X O X O
O X O O O/X
O O X X O
O O X O O/X
O X X O O
Chapter 5                                                                                     Materials and Methods
Department of Pharmacology 41 J.K.K Nattraja College of Pharmacy
Limit Test at 5000 mg/kg
Exceptionally, and only when justified by specific regulatory needs, the use of
a dose at 5000 mg/kg may be considered. For reasons of animal welfare concern,
testing of animals in GHS Category 5 ranges (2000-5000mg/kg) is discouraged and
should only be considered when there is a strong likelihood that results of such a test
have a direct relevance for protecting human or animal health or the environment.
Dose one animal each for the test dose of both test drugs. If the animal dies,
conduct the main test to determine the LD50. If the animal survives, dose two
additional animals each for both test drugs. If both animals survive, the LD50 is
greater than the limit dose and the test is terminated (i.e. carried to full 14-day
observation without dosing of further animals).
If one or both animals die for each drug, then dose an additional two animals
for each test drugs, one at a time. If an animal unexpectedly dies late in the study, and
there are other survivors, it is appropriate to stop dosing and observe all animals to see
if other animals will also die during a similar observation period. Late deaths should
be counted the same as other deaths. The results are evaluated as follows (O=survival,
X=death, and U=Unnecessary).
The LD50 is less than the test dose (5000 mg/kg) when three or more animals die.
O X O X X
O O X X X
O X X O X
O X X X
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The LD50 is greater than the test dose (5000 mg/kg) when three or more animals
survive.
O O O
O X O X O
O X O O
O O X X O
O O X O
O X X O O
5.1.6 OBSERVATIONS
Animals are observed individually at least once during the first 30 minutes
after dosing, periodically during the first 24 hours (with special attention given during
the first 4 hours), and daily thereafter, for a total of 14 days, except where they need
to be removed from the study and humanely killed for animal welfare reasons or are
found dead. However, the duration of observation should not be fixed rigidly. It
should be determined by the toxic reactions and time of onset and length of recovery
period, and may thus be extended when considered necessary. The times at which
signs of toxicity appear and disappear are important, especially if there is a tendency
for toxic signs to be delayed. All observations are systematically recorded with
individual records being maintained for each animal.
Additional observations will be necessary if the animals continue to display
signs of toxicity. Observations should include changes in skin and fur, eyes and
mucous membranes, and also respiratory, circulatory, autonomic and central nervous
systems, and somatomotor activity and behavior pattern. Attention should be directed
to observations of tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma.
The principles and criteria summarized in the Humane Endpoints Guidance Document
should be taken into consideration. Animals found in a moribund condition and
animals showing severe pain or enduring signs of severe distress should be humanely
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killed. When animals are killed for humane reasons or found dead, the time of death
should be recorded as precisely as possible.3
Bodyweight
Individual weights of animals should be determined shortly before the test
substance is administered and at least weekly thereafter for both test drug groups.
Weight changes should be calculated and recorded. At the end of the test surviving
animals are weighed and then humanely killed.
5.1.7 PATHOLOGY
All animals (including those which die during the test or are removed from
the study for animal welfare reasons) should be subjected to gross necropsy. All gross
pathological changes should be recorded for each animal. Microscopic examination of
organs showing evidence of gross pathology in animals surviving 24 or more hours
after the initial dosing may also be considered because it may yield useful
information.23
5.1.8 DATA COLLECTION AND REPORTING
Data
Individual animal data should be provided. Additionally, all data should be
summarized in tabular form, showing for each test dose the number of animals used,
the number of animals displaying signs of toxicity, the number of animals found dead
during the test or killed for humane reasons, time of death of individual animals, a
description and the time course of toxic effects and reversibility, and necropsy
findings. A rationale for the starting dose and the dose progression and any data used
to support this choice should be provided.3
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5.2 NEUROTOXICITY STUDY IN COMBINATION WITH A
REPEATED DOSE SYSTEMIC TOXICITY (HEPATOTOXICITY
AND NEPHROTOXICITY) STUDY
The neurotoxicity study was carried out in combination with a repeated dose
systemic toxicity (hepatotoxicity and nephrotoxicity) study was done according to the
OECD 424 and 407 Guidelines. The description of method and materials used in these
studies are mentioned below.
5.2.1 SELECTION OF ANIMAL SPECIES
The preferred rodent species is the rat, although other rodent species, with
justification, may be used. Commonly used laboratory strains of young adult healthy
animals should be employed. In this study, both male and female wistar rats are used.
The females should be nulliparous and non-pregnant. About 140 rats (70 male and 70
female) are purchased from Kerala Agricultural University, College of Veterinary and
Animal Sciences Mannuthy, Thrissur, Kerala with the registered number
40/072/CPCSEA for both test drugs. Dosing should normally begin as soon as
possible after weaning, preferably not later than when the animals are six weeks, and,
in any case, before the animals are nine weeks of age.. However, when this study is
combined with other studies this age requirement may need adjustment. At the
commencement of the study the weight variation of animals used should not exceed ±
20% of the mean weight of each sex. Where a repeated dose study of short duration is
conducted as a preliminary to a long term study, animals from the same strain and
source should be used in both studies.6
5.2.2 HOUSING AND FEEDING CONDITIONS
The temperature in the experimental animal room should be 22°C (± 3°C).
Although the relative humidity should be at least 30% and preferably not exceed 70%
other than during room cleaning, the aim should be 50-60%. Lighting should be
artificial, the sequence being 12 hours light, 12 hours dark. Loud intermittent noise
should be kept to a minimum. For feeding, food pellets are purchased from Kerala
Agricultural University, College of Veterinary and Animal Sciences Mannuthy,
Thrissur used with an unlimited supply of drinking water. The choice of diet may be
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influenced by the need to ensure a suitable admixture of a test substance when
administered by this method. Animals may be housed individually, or be caged in
small groups of the same sex.2
5.2.3 PREPARATION OF ANIMALS
Healthy young animals are randomly assigned to the treatment and control
groups. Cages should be arranged in such a way that possible effects due to cage
placement are minimized. The animals are identified uniquely and kept in their cages
for at least five days prior to the start of the study to allow for acclimatization to the
laboratory conditions.6
5.2.4 ROUTE OF ADMINISTRATION AND PREPARATION OF DOSES
Route of administration – orally by gavage using a stomach tube or a suitable
intubation cannula.
Vehicle – 3% gum acacia suspension
Preparation of vehicle - 3% gum acacia was prepared prior to the preparation of test
dose by triturating 3g gum acacia in 100 ml distilled water.
Test drugs – swarna makshika bhasma and kasis bhasma was procured from a
renowned ayurvedic pharmaceutical firm having branches abroad also.
Preparation of doses –
The test substances were suspended in 3% gum acacia solution shortly prior to
the administration .The toxic characteristics of vehicle should be known. In addition,
consideration should be given to the following characteristics of the vehicle: effects of
the vehicle on absorption, distribution, metabolism, or retention of the test substance;
effects on the chemical properties of the test substance which may alter its toxic
characteristics; and effects on the food or water consumption or the nutritional status
of the animals.6
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5.2.5 PROCEDURE
Number and sex of animals
The study was conducted as a combination study; at least 20 animals (10
females and 10 males) should be used in each dose and control group for the
evaluation of detailed clinical and functional observations. At least five males and
five females, selected from these 10 males and 10 females, should be perfused in situ
and used for detailed neuro histopathology at the end of the study. In cases where only
a limited number of animals in a given dose group are observed for signs of
neurotoxic effects, consideration should be given to the inclusion of these animals in
those selected for perfusion. When the study is conducted in combination with a
repeated dose toxicity study, adequate numbers of animals should be used to meet the
objectives of both studies. If interim kills or recovery groups for observation of
reversibility, persistence or delayed occurrence of toxic effects post treatment are
planned or when supplemental observations are considered, then the number of
animals should be increased to ensure that the number of animals required for
observation and histopathology are available.6
Treatment and control groups
In this study three dose groups and a control group was used for each test
drug. But if from the assessment of other data, no effects would be expected at a
repeated dose of 1000 mg/kg body weight/day, a limit test may be performed. If there
are no suitable data available, a range finding study may be performed to aid in the
determination of the doses to be used. Except for treatment with the test substance,
animals in the control group should be handled in an identical manner to the test
group subjects. If a vehicle is used in administering the test substance, the control
group should receive the vehicle at the highest volume used.6
Reliability check
The laboratory performing the study should present data demonstrating its
capability to carry out the study and the sensitivity of the procedures used. Such data
should provide evidence of the ability to detect and quantify, as appropriate, changes
in the different end points recommended. Historical data may be used if the essential
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aspects of the experimental procedures remain the same. Periodic updating of
historical data is recommended. New data that demonstrate the continuing sensitivity
of the procedures should be developed when some essential element of the conduct of
the test or procedures has been changed by the performing laboratory.6
Dose selection
Dose levels should be selected by taking into account any previously observed
toxicity and kinetic data available for the test compound or related materials. The
highest dose level should be chosen with the aim of inducing neurotoxic, hepatotoxic
and nephrotoxic effects or clear systemic toxic effects. Thereafter, a descending
sequence of dose levels should be selected with a view to demonstrating any dose-
related response and a no-observed-adverse effect (NOAEL) at the lowest dose level.
The groups and dose selected for this study was
Swarna makshika bhasma - Group 1 - 250 mg/kg
Group 2 - 500 mg/kg
Group 3 - 1000 mg/kg
Kasis bhasma - Group 1 - 250 mg/kg
Group 2 - 500 mg/kg
Group 3 - 1000 mg/kg
Control (3% gum acacia suspension) - Group 4
Limit test
If a study at one dose level of at least 1000 mg/kg body weight/day, using the
procedures described, produces no observable neurotoxic, hepatotoxic and
nephrotoxic  effects and if toxicity would not be expected based upon data from
structurally related compounds, then a full study using three dose levels may not be
considered necessary. Expected human exposure may indicate the need for a higher
oral dose level to be used in the limit test. For other types of administration, such as
inhalation or dermal application, the physical chemical properties of the test substance
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often may dictate the maximum attainable level of exposure. For the conduct of an
oral acute study, the dose for a limit test should be at least 2000 mg/kg.6
Administration of doses
The animals are dosed with the test substance daily, seven days each week,
for a period of at least 28 days. The test substance was administered by gavage, this
should be done in a single dose using a stomach tube or a suitable intubation cannula.
The maximum volume of liquid that can be administered at one time depends on the
size of the test animal. The volume test drug administered was 1 ml/100 g body
weight. For a substance administered by gavage, the dose should be given at similar
times each day, and adjusted as necessary to maintain a constant dose level in terms of
animal body weight.Where a repeated dose study is used as a preliminary to a long
term study, a similar diet should be used in both studies.6
5.2.6 OBSERVATIONS
Frequency of observations and tests
In repeated dose studies, the observation period should cover the dosage
period. Observations should be made with sufficient frequency to maximize the
probability of detection of any behavioral and/or neurological abnormalities.
Observations should be made preferably at the same times each day with
consideration given to the peak period of anticipated effects after dosing.
Observations of general health condition and mortality/morbidity
All animals should be carefully observed at least once daily with respect to
their health condition as well as at least twice daily for morbidity and mortality.
5.2.7 DETAILED CLINICAL OBSERVATIONS
Detailed clinical observation was done on both test drug treated groups once
before the first exposure (to allow for within-subject comparisons) and at different
intervals thereafter, for 28 days study. Detailed clinical observations should be made
outside the home cage in a standard arena. In this study standard arena used was open
field arena.
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Open field test
The behaviour of animals was studied by means of open field test (ambulation,
grooming, rearing, object exploration, defecation score) , four times: prior to
exposure, after one week, two weeks, and four weeks of the experiment. Parallelly, a
group of unexposed animals kept in the same condition was tested as a control. The
open field arena was circular, 85 cm in diameter, with a white floor and a 50 cm high
white wall. The floor had three concentric black circles, and the two outer circles were
divided into segments by six radiating lines. Six additional short radiating lines
subdivided all of the segments in the outermost circle into two, resulting in a total of
19 sections of equal area in the floor. The light level was 310 lux. For testing, each
animal was placed on a   starting point in the centre of one of the middle circle
segments and then observed for 2 min. The number of the floor sections visited by the
rat with all four feet, the number of rearing to the hind paws, and the number of faeces
boluses were recorded.25
Fig: 5.1 circular open field apparatus
Effort was made to ensure that variations in the test conditions are minimal
(not systematically related to treatment) and that observations are conducted by
trained observers unaware of the actual treatment. Clinical observations should
include, but not be limited to, changes in skin, fur, eyes, mucous membranes,
occurrence of secretions and excretions and autonomic activity (e.g., lacrimation,
piloerection, pupil size, unusual respiratory pattern and/or mouth breathing, any
unusual signs of urination or defecation, and discolored urine). Any unusual responses
with respect to body position, activity level (e.g., decreased or increased exploration
of the standard arena) and co-ordination of movement should also be noted. Changes
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in gait (e.g., waddling, ataxia), posture (e.g., hunched-back) and reactivity to
handling, placing or other environmental stimuli, as well as the presence of clonic or
tonic movements, convulsions or tremors, stereotypes (e.g., excessive grooming,
unusual head movements, repetitive circling) or bizarre behavior (e.g., biting or
excessive licking, self-mutilation, walking backwards, vocalization) or aggression
should be recorded.25
5.2.8 FUNCTIONAL TESTS
Functional tests for 28 days study was conducted once prior to exposure and
during the fourth week of treatment as close as possible to the end of the exposure
period. Functional tests should include sensory reactivity to stimuli of different
modalities [e.g., auditory, visual and proprioceptive stimuli assessment of limb grip
strength and assessment of motor activity.
Assessment of limb grip strength
Assessment of limb grip strength was done by rote rod apparatus.
Rota rod test
The apparatus consist of a Rotating rod diameter is ca. 5cm made of hard
plastic material covered by grey rubber foam lanes width is ca. 5cm. The apparatus
must allow an accelerating speed from 4rpm to 40rpm in 300 sec.
Fig; 5.2 Rotarod apparatus.
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The limb grip strength was assessed by means of rota rod testing, two times;
prior to exposure and fourth week of treatment for both test drugs. parallely a group of
un exposed animals also assessed for limb grip strength. On the day of testing, mice
had been kept in their home cages and acclimate to the testing room for at least 15
min. Three trials separated by 15 min inter-trial intervals (ITI) were conducted for all
groups. For testing rota rod was turned on at an appropriate speed (20-25) .animals
was placed one by one on the rotating rod.  ‘Fall of time’ was recorded when the rat
falls from the rotating rod. Similarly fall of time was recorded at the fourth week of
treatment also. At the end of each test, the rotorod is cleaned with 70% alcohol
solution, and dried with paper toweling. Fall off time before and after treatment was
compared and % decrease in time was calculated for both test drugs.26
Assessment of motor activity
Assessment of motor activity was done using actophotometer.
Actophotometer
It consist of six built in photo electric cells which are connected in circuit with
a counter .when the beam of light falling on the photocell was cut off by the animal , a
count is recorded. The locomotor activity was assessed by means of actophotometer
testing, two times; prior to exposure and fourth week of treatment for both test drugs.
parallely a group of un exposed animals also assessed for motor activity.
Fig: 5.3 Actophotometer.
Chapter 5                                                                                     Materials and Methods
Department of Pharmacology 52 J.K.K Nattraja College of Pharmacy
Testing
Actophotometer was turned on (check and make sure that all the photocells are
working for accurate recording) and each rat was placed individually in the activity
cage for 10min.Basal activity score of all the animals was recorded. Similarly basal
activity score at fourth week of exposure was also recorded. Difference in the activity
before and after treatment of both the test drugs was compared and % decrease in
activity was calculated.26
5.2.8 BODY WEIGHT AND FOOD/WATER CONSUMPTION
For studies of 28 days duration, all animals should be weighed at least once a
week and measurements should be made of food consumption (water consumption,
when the test substance is administered by that medium) at least weekly.6
5.2.9 CLINICAL BIOCHEMISTRY
When the neurotoxicity study is carried out in combination with a repeated
dose systemic toxicity (hepatotoxicity and nephrotoxicity) study clinical biochemistry
determinations should be carried out as set out in the respective Guideline of the
systemic toxicity study. Collection of samples should be carried out in such a way that
any potential effects on neurobehaviour are minimized.
Clinical biochemistry determinations to investigate major toxic effects in
tissues and, specifically, effects on kidney and liver, should be performed on blood
samples obtained of all animals just prior to or as part of the procedure for killing the
animals (apart from those found moribund and/or intercurrently killed). All surviving
animals fasted overnight and were anesthetized afterwards for blood collection from
retro-orbital. Blood samples were collected into dry non-heparinized centrifuge tubes.
The non-heparinized blood was allowed to coagulate before being centrifuged and the
serum was separated. The serum was assayed for creatinine, blood urea nitrogen
(BUN), aspartate transaminase (AST), alanine transaminase (ALT), alkaline
phosphatases (Alk-P), total bilirubim and direct bilirubin. 27
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5.2.10 PATHOLOGY
Gross necropsy
When the neurotoxicity study is carried out in combination with a repeated
dose systemic toxicity (hepatotoxicity and nephrotoxicity). Tissues from at least 10
animals (5 males and 5 females)/group were subjected to detailed gross necropsy. The
brain, kidney and liver of all animals selected should be trimmed of any adherent
tissue, as appropriate, and their wet weight taken as soon as possible after dissection
to avoid drying. The following tissues should be preserved in the most appropriate
fixation medium for both the type of tissue and the intended subsequent
histopathological examination.
Histopathology
The neuropathological examination should be designed to complement and
extend the observations made during the in vivo phase of the study. Tissues from at
least 10 animals (5 males and 5 females)/group should be fixed in situ, using
generally recognized perfusion and fixation techniques. A stepwise examination of
tissue samples is recommended in which sections from the high dose group are first
compared with those of the control group. If no neuropathological alterations are
observed in the samples from these groups, subsequent analysis is not required. If
neuropathological alterations are observed in the high dose group, samples from each
of the potentially affected tissues from the intermediate and low dose groups should
then be coded and examined sequentially. The areas examined for brain should
normally include: the forebrain, the centre of the cerebrum, including a section
through the hippocampus, the midbrain, the cerebellum, the pons and the medulla
oblongata. The neuropathological findings should be evaluated in the context of
behavioural observations and measurements, as well as other data from preceding and
concurrent systemic toxicity studies of the test substance.
For hepatotoxicity and nephrotoxicity histopathology should be carried out on
the preserved liver and kidney respectively of all animals in the control and high dose
groups. These examinations should be extended to animals of all other dosage groups,
if treatment-related changes are observed in the high dose group. All gross lesions
shall be examined.6, 4
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5.2.11 STATISTICAL ANALYSIS
Results were expressed as mean ± standard deviation. (S.D.) In acute and sub
acute toxicity, statistical significance was determined by one-way analysis of variance
(ANOVA) and Dunnett test. P values less than 0.05 were considered significant.
5.2.12 DATA
When the neurotoxicity study is carried out in combination with a repeated
dose systemic toxicity (hepatotoxicity and nephrotoxicity). Individual data should be
provided. Additionally, all data should be summarized in tabular form showing for
each test or control group the number of animals at the start of the test, the number of
animals found dead during the test or killed for humane reasons and the time of any
death or humane kill, the number showing signs of toxicity, a description of the signs
of toxicity observed, including time of onset, duration, type and severity of any toxic
effects, the number of animals showing lesions, including the type and severity of the
lesions. When possible, numerical results should be evaluated by an appropriate and
generally acceptable statistical method. The statistical methods should be selected
during the design of the study.6,4
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CHAPTER 6
RESULTS AND DISCUSSION
6.1 ACUTE TOXICOLOGICAL STUDIES
6.1.1 PRELIMINARY OBSERVATION OF ANIMALS ADMINISTERED
SWARNA MAKSHIKA BHASMA AND KASIS BHASMA (OECD
GUIDELINES 425)
Animals are observed individually during the first 30 minutes after dosing and
with special attention given during the first 4 hours. The animals show different
behavior changes after administration of both test drugs. The following table’s shows
sign of toxicity produced by animals administered swarna makshika bhama and kasis
bhasma.3
6.1.2 LIMIT TEST AT 2000mg/kg
In this limit test, 5 swiss albino mice’s are used for each test drugs. Procedure
for the limit test was discussed in chapter 5. The results of the observation are
tabulated in table 6.1. Observations include changes in skin and fur, eyes and mucous
membranes, and also respiratory, circulatory, autonomic, somatomotor activity and
behavior pattern. Attention also is directed to observations in tremors, convulsions,
salivation, diarrhoea, lethargy and sleep. No animal found dead during experiment.
OBSERVATION AT LIMIT TEST 2000mg/kg
TEST DRUGS SWARNA
MAKSHIKA
BHASMA
KASIS BHASMA
RESPIRATORY BLOCKAGE IN NOSTRIL
DYSPNOEA - -
APNOEA - -
TACHYPNEA - -
NOSTRIL DISCHARGE + +
MOTOR ACTIVITIES
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LOCOMOTION - +
SOMNOLENCE - +
LOSS OF RIGHTING REFLEX - -
ANAESTHESIA - -
CATALEPSY - -
ATAXIA - -
TOE WALKING - -
PROSTRATION - +
FASCICULATION - +
TREMOR - -
HIND LIMB PARESIS - -
CONVULSION (IN VOLUNTARY CONTRACTION)
CLONIC/TONIC/TONIC-CLONIC
CONVULSION
- -
ASPHYXIAL CONVULSION - -
OPISTOTONES(TITANIC SPASM) - -
REFLEXES
CORNEAL - -
EYELID CLOSURE - -
RIGHTING - -
LIGHT - -
AUDITORY AND SENSORY - -
OCULAR SIGNS
LACRIMATION - -
MIOSIS - -
MYDRIASIS - -
PTOSIS - -
CHROMODACRYORRHEA - -
IRITIS - -
CONJUNCTIVITIS - -
CVS SIGN
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Table 6.1 Observation at limit test 2000mg/kg
6.1.3 LIMIT TEST AT 5000mg
In this limit test, 3 Swiss albino mice’s are used for testing of both bhasmas.
Procedure for the limit test was discussed in chapter 5. The results of the observation
are tabulated in the following table 6.2. Observations include changes in skin and fur,
eyes and mucous membranes, and also respiratory, circulatory, autonomic,
HEART RATE - -
VASODILATION - -
VASOCONSTRICTION - -
ARRHYTHMIA - -
SALIVATION
SALIVA SECRETION + +
PILOERECTION
CONTRACTION OF ERECTILE
TISSUE
- -
ANALGESIA
DECREASE IN REDUCTION TO
INDUCE PAIN
- +
MUSCLE TONE
HYPO OR HYPERTONIA - -
GIT SIGN
WATERY STOOL - -
EMESIS - -
RED URINE - -
RED STOOLS + +
SKIN
DISCOLORATION OF SKIN - -
ERYTHEMA - -
DEATH - -
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somatomotor activity and behavior pattern. Attention also is directed to observations
in tremors,   convulsions, salivation, diarrhoea, lethargy and chocking. All animals
died within 10   minutes of    Swarna makshika and kasis bhasma administrations.3
OBSERVATION AT LIMIT TEST 5000mg/kg
TEST DRUGS SWARNA
MAKSHIKA
BHASMA
KASIS BHASMA
RESPIRATORY BLOCKAGE IN NOSTRIL
DYSPNOEA - -
APNOEA - -
TACHYPNEA - -
NOSTRIL DISCHARGE + +
MOTOR ACTIVITIES
LOCOMOTION + +
SOMNOLENCE - +
LOSS OF RIGHTING REFLEX - -
ANAESTHESIA - +
CATALEPSY - -
ATAXIA - -
TOE WALKING - -
PROSTRATION + +
FASCICULATION + +
TREMOR - -
HIND LIMB PARESIS + +
CONVULSION (IN VOLUNTARY CONTRACTION)
CLONIC/TONIC/TONIC-CLONIC
CONVULSION
- -
ASPHYXIAL CONVULSION - -
OPISTOTONES(TITANIC SPASM) - -
REFLEXES
CORNEAL + +
EYELID CLOSURE + +
Chapter 6 Result and discussion
Department of Pharmacology 59 J.K.K Nattraja College of Pharmacy
RIGHTING - -
LIGHT - -
AUDITORY AND SENSORY - -
OCULAR SIGNS
LACRIMATION - -
MIOSIS - -
MYDRIASIS - -
PTOSIS - -
CHROMODACRYORRHEA - -
IRITIS - -
CONJUNCTIVITIS - -
CVS SIGN
HEART RATE - -
VASODILATION - -
VASOCONSTRICTION - -
ARRHYTHMIA - -
SALIVATION
SALIVA SECRETION + +
PILOERECTION
CONTRACTION OF ERECTILE
TISSUE - -
ANALGESIA
DECREASE IN REDUCTION TO
INDUCE PAIN
+ +
MUSCLE TONE
HYPO OR HYPERTONIA - -
GIT SIGN
WATERY STOOL - -
EMESIS + +
RED URINE - -
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Table 6.2 Observation at limit test 5000mg/kg
6.1.4 RESULT
From the above observations, it’s clear that the swarna makshika and kais
bhasma shows some toxic reaction in animals. Especially kasis bhasma shows
neurotoxicity symptoms like decreased locomotor activity, hind limb paresis etc. At
limit test 2000mg/kg, no death is observed. Hence the LD50 of swarna makshika and
kasis bhasma was found to be greater than 2000mg/kg. But at limit test 5000mg/kg,
all animals died during experiment. So the LD50 is below 5000mg/kg. Hence from the
above observations we can conclude that the LD50 of swarna makshika and kasis
bhasma was between 2000mg/kg and 5000mg/kg.
RED STOOLS + +
SKIN
DISCOLORATION OF SKIN - -
ERYTHEMA - -
DEATH + +
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6.2 OBSERVATIONS OF NEUROTOXICITY STUDY IN
COMBINATION WITH A REPEATED DOSE SYSTEMIC
TOXICITY (HEPATOTOXICITY AND NEPHROTOXICITY)
STUDY (GUIDELINES 424,407) OF SWARNA MAKSHIKA
BHASMA AND KASIS BHASMAS.
In this test, 140 wistar rats are used. 20 rats each are used in four different
groups such as control, 250mg/kg, 500mg/kg, and 1000mg/kg for both swarna
makshika and kasis bhasma. In this, each group contain 10 male and 10 female rats.
Procedure for the limit test was discussed in chapter 5. The results of the observation
are tabulated in the following table 6.3. Observations include changes in skin and fur,
eyes and mucous membranes, and also respiratory, circulatory, autonomic,
somatomotor activity and behavior pattern. Attention also is directed to observations
in tremors, convulsions, salivation, diarrhoea, lethargy and sleep.
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6.2.1 BODY WEIGHT ANALYSIS
Weights of all animals are noted everyday. Difference in weight in different
doses of animal and noted and recorded. The below table shows the body weight
analysis of rats in the sub acute toxicity studies of yellow cow dung powder.
DRUG
USED
GROUPS DAY 0
gm
DAY 7
gm
DAY 14
gm
DAY 28
gm
Total
weight
gain
gm
CONTROL 125±10.42 155±11.2 165±12.5 180±10 55±1.667
SW
A
R
N
A
 
 
M
A
K
SH
IK
A
 
BH
A
SM
A
250mg/kg 123.7±2.44 130.5±3.91 160±5.09 165.5±5.244 42±2.87
500mg/kg 121.5±2.37 146.5±4.848 153.75±6.09 160.7±10.41 39±8.04
1000mg/kg 148.7±7.31 160.2±5.543 166.2±2.5 170.2±5.00 22±2.31
K
A
SI
S 
BH
A
M
A 250mg/kg 141.2±3.5 153.7±5.5 165±4.6 182±9.4 40.8±5.9
500mg/kg 148.7±4.19 158.7±2.3 148.7±8.22 165.7±5.8 17±1.61
1000mg/kg 158.7±5.2 160.7±11.5 170±4.7 170.5±2.4 11.8±2.8
Table 6.3 body weight analysis
Results are expressed in mean: n=20, * significant at p < 0.05, ** significant at p
<0.01, *** significant at p < 0.001.
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6.2.2 FOOD CONSUMPTION GRAPH
During the experiment, the mean daily food consumption of individual rats is
recorded. The following graphs show the daily food consumption of rats in different
groups like control, 250mg/kg, 500mg/kg, and 1000mg/kg of swarna makshika
bhasma and kasis bhasma.
Graph 6.1 days v/s food consumption in gm for Kasis bhasma treated groups
Graph 6.2 days v/s food consumption in gm for Swarna makshika bhasma treated
groups.
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6.2.3 WATER CONSUMPTION GRAPH
During the experiment, the mean daily water intake of individual rats was
recorded. The following graphs show the daily water intake of rats in different groups
like control, 250mg/kg, 500mg/kg, and 1000mg/kg of both the test drugs.
Graph 6.3 days v/s water intake in ml for kasis bhasma treated groups
Graph 6.2 days v/s water intake in ml for swarna makshika treated group
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6.2.4 DETAILED CLINICAL OBSEVATIONS
Open field test
The behavior of animals was studied by means of open field test (ambulation,
grooming, rearing, object exploration, defecation score) , four times: prior to
exposure, after one week, two weeks, and four weeks of the experiment. Parallelly, a
group of unexposed animals kept in the same condition was tested as a control.
A -ambulation; B - grooming; C - rearing; D – defecation
Table 6.4 open field test
Results are expressed in mean: n=20, * significant at p < 0.05, ** significant at p
<0.01.
Examined
Groups
CONTRO
L
KASIS BHASMA
SWARNA
MAKSHIKA  BHASMA
250
mg/kg
500
mg/kg
1000
mg/kg
250
mg/kg
500
mg/kg
1000
mg\kg
Prior to
Exposure
A 38.3±11.05 36.2±8.04 40±6.82 51.4±12.42 44.4±8.43 48.2±7.25 47.8±10.349
B 2.00±0.57 3.00±0.62 2.00±0.50 1.9±0.20 3.2±0.67 2.8±0.68 2.4±0.56
C 18.20±3.12 16..4±2.40 16.2±2.2 13.2±2.2 19.4±2.1 19.8±3.4 18.2±2.8
D 2.40±0.87 2.50±0.54 2.8±0.62 3.00±0.24 2.8±0.64 2.5±0.45 2.4±0.54
After 1
Week
Exposure
A 38±8.71 30.2±6.4 21.4±9.42 24.4±14.2 38±11.4 31±12.04 26.4±5.02
B 2.00±0.91 2.4±0.45 2.8±0.64 2.2±0.54 1.5±0.62 2.6±0.24 2.00±0.68
C 6.00±2.54 10.4±4.62 11.2±6.31 8.62±3.2 15.2±2.84 13.2±4.2 14.2±3.4
D 3.20±1.39 2.8±0.94 4.2±1.50 4.8±2.2 3.2±1.1 5.2±0.67 2.2±1.2
After 2
Week
Exposure
A 40±8.05 25.2±9.4 17.2±6.23 24.4±14.45 37±8.4 31±6.04 23.8±11.2
B 1.40±0.45 1.2±0.20 2.2±0.89 2.4±0.62 3.2±1.2 2.1±0.022 1.9±0.69
C 9.60±1.80 8.2±1.4 4.2±0.43 5.4±1.72 12.2±1.8 14.2±0.56 15.8±2.8
D 1.40±0.93 1.9±0.89 3.2±0.52 3.9±2.48 2.9±0.68 1.9±0.56 1.5±.97
After 4
Week
Exposure
A 40±12.95 24.1±11.2 14.4±8.42 19.2±8.45 34±11.23 28±9.42 22±6.29
B 1.20±0.29 1.2±0.52 1.8±0.89 2.1±0.67 1.9±1.2 1.6±0.41 1.9±0.24
C 4.70±1.20 6.4±1.9 8.9±0.81 12.2±0.92 4.2±0.21 6.2±1.8 6.9±1.6
D
1.90±0.86 1.2±0.20 1.5±0.68 2.9±0.92 1.8±0.54 2.00±1.7 1.9±0.65
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6.2.5 FUNCTIONAL TESTS OBSERVATION
Assessment of limb grip strength (rota rod test)
The limb grip strength was assessed by means of rota rod testing, two times;
prior to exposure and fourth week of treatment for both test drugs. parallely a group of
un exposed animals also assessed for limb grip strength. Fall off time before and after
treatment was compared and % decrease in time was calculated for both test drugs.
DRUGS
USED
GROUPS
FALL OFF TIME(SEC)
%CHANGE
IN
FALL OFF
TIME
BEFORE
DRUG
EXPOSURE
AT 4th WEEK
OF
EXPOSURE
K
A
SI
S 
 
B
H
A
SM
A
control 101.8±5.12 100.53 ±2.3 1.24% ↓
250mg/kg 85.416±6.43 82.858±7.45 3% ↓
500mg/kg 111.86±8.2 39.4±3.2 64.24% ↓
1000mg/kg 173.8±6.2 55±7.2 68.35% ↓
SW
A
R
N
A
M
A
K
SH
IK
A
B
H
A
SM
A
250mg/kg 78.686±2.52 74.38±4.2 5.4% ↓
500mg/kg 73.46±2.2 62.54±7.8 14.86% ↓
1000mg/kg 89.812±5.62 75.92±8.42 15.46% ↓
Table 6.5 rota rod test
Results are expressed in mean: n=20, * significant at p < 0.05, ** significant at p
<0.01
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Graph 6.5   % change in fall of time vs. dose administered by both bhasmas
Assessment of locomotor activity
The locomotor activity was assessed by means of actophotometer testing, two
times; prior to exposure and fourth week of treatment for both test drugs. Parallely a
group of unexposed animals also assessed for motor activity. Difference in the
activity before and after treatment of both the test drugs was compared and %
decrease in activity was calculated.
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DRUGS USED
GROUPS
LOCOMOTOR
ACTIVITY SCORES IN 10 MIN %CHANGE
IN
LOCOMOTOR
ACTIVITY
BEFORE DRUG
EXPOSURE
AT 4th WEEK
OF
EXPOSURE
K
A
SI
S 
 
B
H
A
SM
A
control 64±4.3 61 ±5.2 1.63% ↓
250mg/kg 72.2±8.2 71.2±4.2 1.38% ↓
500mg/kg 82.6±4.3 31±6.4 62.5% ↓
1000mg/kg 182±9.2 65±5.4 64.2% ↓
SW
A
R
N
A
M
A
K
SH
IK
A
B
H
A
SM
A
250mg/kg 57.2±3.2 55.2±4.2 4.49% ↓
500mg/kg 56.2±7.2 52.2±5.3 7.1% ↓
1000mg/kg 77.2±3.5 68.2±4.4 11.6% ↓
Table 6.6   assessment of locomotor activity
Results are expressed in mean: n=20, * significant at p < 0.05, ** significant at p
<0.01
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Graph 6.6   % change in locomotor activity vs. dose administered for both bhasmas
6.2.6 CLINICAL BIOCHEMISTRY
When the neurotoxicity study is carried out in combination with a repeated
dose systemic toxicity (hepatotoxicity and nephrotoxicity) study clinical biochemistry
determinations should be carried out as set out in the respective Guideline of the
systemic toxicity study. Blood samples are collected from eye orbital of rats before
dosing commenced, at the end of 28 day administration period. Biochemical studies
are performed at laboratory in Giri micro labortary Gandhi nagar, Erode,Tamil Nadu.
Clinical biochemical analyses of blood included creatinine, blood urea nitrogen
(BUN), aspartate transaminase (AST), alanine transaminase (ALT), alkaline
phosphatases (Alk-P), total bilirubin,direct bilirubin.
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6.2.7 BIOCHEMICAL EXAMINATION
TESTS CONTROL
KASIS
BHASMA
SWARNA MAKSHIKA
BHASMA
250
mg/kg
500
mg/kg
1000
mg/kg
250
mg/kg
500
mg/kg
1000
Mg/kg
UREA
(mgs/dl)
51±1 50±2 51±5 52±3 55±6 50±3 46± 2
CREATININE
(mgs/dl)
1.7±0.10 1.5±0.40 1.1±0.25 0.8±0.90 1.2±0.31 0.9±0.22 0.6±0.41
S.G.O.T
(IU/L)
130.9±0.50 135±0.60 138±0.80
195±0.40***
140±0.67*
**
160±0.92*
**
188±0.21
***
S.G.P.T
(IU/L)
61.8±1.00 59±2.5 58±1.43 60±1.58 56±2.3 59±3.1 66±1.2
ALKALINE
PHOSPHATASE
(IU/L)
150.6±1.00 170±1.52 180±2.24
198±2.14***
210±1.3*** 290±0.87*
**
353±0.94
***
DIRECT
BILIRUBIN
(mg/dl)
0.32±0.005 0.4±0.021 0.6±0.041 0.8±1.2 0.5±0.002 0.6±0.05
0.9±0.00
2
TOTAL
BILIRUBIN
(mg/dl)
0.53±0.005 0.6±0.009 0.8±0.010 0.82±0.12 0.7±0.008 0.9±0.009
**
1.1±0.00
6***
Table 6.7   bio chemical examinations
Results are expressed in mean: n=20, * significant at p < 0.05, ** significant at p
<0.01,*** significant at P<0.001.
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6.2.8 ORGAN WEIGHT DATA
Tissues from at least 10 animals (5 males and 5 females)/group was subjected
to a detailed gross necropsy. The liver, kidneys and brain of all animals are subjected
to be trimmed of any adherent tissue, as appropriate, and their wet weight taken as
soon as possible after dissection to avoid drying. The following table shows the net
organ weight of treated and control animal
ORGANS CONTROL
gm
KASIS BHASMA SWARNA MAKSHIKA BHASMA
250
mg/kg
gm
500
mg/kg
gm
1000
mg/kg
gm
250
mg/kg
gm
500
mg/kg
gm
1000
mg/kg
gm
LIVER 6.01±0.0114 5.04±0.0
1241
5.62±0.0154 4.76±.014
24
5.66±.0084 6.08±0.01042 7.458±0.0
223**
KIDNEY 0.58±0.01025 0.60±0.0
146
0.50±0.01051 0.56±.014
02
0.67±0.0145 0.53±0.0102 0.61±0.01
04
BRAIN 1.531±0.0142 1.45±0.0
1256
1.53±0.01247 1.65±.004
2
1.65±0.0152
1.21±0.0024 1.53±0.00
42
Table 6.8 organ weight data
Results are expressed in mean: n=10, * significant at p < 0.05, ** significant at p
<0.01, *** significant at p < 0.001
6.2.9 HISTOPATHOLOGICAL STUDIES
Tissues from at least 10 animals (5 males and 5 females)/group was subjected to
detailed gross necropsy. The brain, kidney and liver of all animals selected should be
trimmed of any adherent tissues. The following tissues should be preserved in the
most appropriate fixation medium for both the type of tissue and the intended
subsequent histopathological examination.
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LIVER
A. Control:
SWARNA MAKSHIKA BHASMA KASIS BHASMA
A1.1000mg/kg A2.1000mg/kg
A3.500mg/kg A4.500mg/kg
A5. 250mg/ kg A6.250mg/kg
Fig 6.1(A-A6)-Histopathology of liver
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KIDNEY
B. Control:
SWARNA MAKSHIKA BHASMA KASIS BHASMA
B1.1000mg/kg B2.1000mg/kg
B3.500mg/kg B4.500mg/kg
B5. 250mg/kg B6.250mg/kg
Fig 6.2(B-B6)-histopathology of kidney
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BRAIN
C. Control:
SWARNA MAKSHIKA BHASMA KASIS BHASMA
C1.1000mg/kg C2.1000mg/kg
C3.500mg/kg C4 .500mg/kg
C5.250mg/kg C6.250mg/kg
Fig 6.3(C-C6)-histopathology of brain
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DISCUSSION
ACUTE ORAL TOXICITY STUDIES (guidelines 425)
LIMIT TEST AT 2000mg/kg
In this limit test, 5 Swiss albino mice’s are used. Observations include (table
6.1) changes in skin and fur, eyes and mucous membranes, and also respiratory,
circulatory, autonomic, somatomotor activity and behavior pattern are observed. Kasis
bhasma when compared with swarna makshika bhasma and control shows little
changes in motor activity. No animal found dead during experiment.
LIMIT TEST AT 5000mg/kg
In this limit test, 2 Swiss albino mice’s are used. Observations (table 6.2)
include changes in skin and fur, eyes and mucous membranes, and also respiratory,
circulatory, autonomic, somatomotor activity and behavior pattern. Attention also is
directed to observations in tremors, convulsions, salivation, diarrhea, hind limb
paresis, lethargy and chocking. In both bhasmas sign of neurotoxicity was observed.
Both test drugs shows hind limb paresis, changes in motor activity and red stools.
Both animals died within 10 minutes of drug administration.
From the above observations, it’s clear that both kasis bhasma and swarna
makshika bhasma shows toxic reaction in animals. At limit test 2000mg/kg, no death
is observed. Hence the LD50 of both test drugs was greater than 2000mg/kg. But at
limit test 5000mg/kg, all animals died during experiment. So the LD50 is below
5000mg/kg. Hence from the above observations we can conclude that the LD50 of
kasis bhasma and swarna makshika bhasma is between 2000mg/kg and 5000mg/kg.
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NEUROTOXICITY STUDY IN COMBINATION WITH A
REPEATED DOSE SYSTEMIC TOXICITY (HEPATOTOXICITY
AND NEPHROTOXICITY) STUDY
OBSERVATIONS
BODY WEIGHT ANALYSIS
Body weight indicates the health status of any living being. Here weights of
all animals are noted everyday. Difference in weight in different doses of animal were
noted and recorded for both test drugs. In the neurotoxicity study combined with
hepatotoxicity and nephrotoxicity average body weight gain in swarna makshika and
kasis bhasma  treated groups of rats showed a slight decrease in high( 1000mg/kg)
doses when compared to control, but the decrease in weight is non significant. So
body weight analysis of this study could suggest that there are no or less harmful
effects of test drugs on body function as a whole.28
FOOD/WATER CONSUMPTION
Food/ water consumption of all rats are noted everyday. In the neurotoxicity
study in combination with hepato and nephrotoxicity study, the food/water
consumption of swarna makshika and kasis bhasma treated groups of rats showed a
slight decrease but was not significantly different from those of the control group.
Analysis of food and water consumption by treated rats doesn’t shows any signs of
toxicity.
DETAILED CLINICAL OBSEVATIONS
Open Field Test
The behavior of animals was studied by means of open field test (ambulation,
grooming, rearing, defecation score) , four times: prior to exposure, after one week,
two weeks, and four weeks of the experiment. Parallelly, a group of unexposed
animals kept in the same condition was tested as a control.
The results of the present study (table 6.4) showed that both kasis and swarna
makshika bhasma does not produce any significant differences in the open field test
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statistically. However kasis bhasma showed a slight variation in the observed
ambulation of tested rats when compared with other parameters. From this above
observations it’s clear that there were no differences in the measures of anxiety and
emotionality statistically. So there was no significant influence for both this bhasmas
on the behavior of animals in open field test was noted.29
Functional tests observation
Assessment of Limb Grip Strength
The limb grip strength was assessed by means of rota rod testing, two times;
prior to exposure and fourth week of treatment for both test drugs. parallely a group of
un exposed animals also assessed for limb grip strength. Fall off time before and after
treatment was compared and % decrease in time was calculated for both test drugs.
Fall off time before and after treatment was compared and % decrease in time was
calculated for both test drugs.
The results of present study (table 6.5) showed that animal from high dose
treatment groups 500mg/kg and 1000mg/kg of kasis bhasma shows a significant
decrease in % fall off time that is 64.24% and 68.35% respectively. However there
were no differences in the limb grip strength for swarna makshika treated groups
when compared with control by rota rod test.
Assessment of Locomotor Activity
The locomotor activity was assessed by means of actophotometer testing, two
times; prior to exposure and fourth week of treatment for both test drugs. Parallely a
group of unexposed animals also assessed for motor activity. Difference in the
activity before and after treatment of both the test drugs was compared and %
decrease in activity was calculated.
The results of present study (table 6.6) showed that animal from high dose
treatment groups 500mg/kg and 1000mg/kg of kasis bhasma shows a significant
decrease in the % change of locomotor activity that is 62.5% and 64.2% respectively.
However there were no differences in the motor activity for swarna makshika treated
groups when compared with control by rota rod test.
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CLINICAL BIOCHEMISTRY
The liver and kidney are one of the major internal organs in the body and have
several important functions. Symptoms of disorder in those organs appear only in
serious diseases. To test whether the substance destroys and impairs liver and kidney
functions, clinical blood chemistry examination was performed in the female and
male rats.
All surviving animals fasted overnight and were anesthetized afterwards for
blood collection from retro-orbital. Blood samples were collected into dry non-
heparinized centrifuge tubes.The separated  serum was assayed for creatinine, blood
urea nitrogen (BUN), aspartate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatases (Alk-P), total bilirubin, direct bilirubin .
Effect on kidney
There was no adverse effect on renal function after the administration of two
different bhasmas(swarna makshika and kasis bhasma). Biochemical parameters
revealed that excretory function of kidney was well maintained, as there was no rise
in the values of blood urea nitrogen (BUN), and serum creatinine levels in plasma of
rats treated with above-mentioned drugs.
Effect on liver
Two different bhasmas used in this study showed little disturbance in hepatic
functions as compared to control group rats. Table 6.7 represents the changes in the
activities of SGOT, SGPT, ALP, TBL and direct bilirubin. In the assessment of
hepatotoxicity the determination of enzyme levels such as aspartate transaminase and
alanine transaminase is largely used. The results of present study showed that all the
dose range of  swarna makshika bhasma treated group had a significant increase in the
S.G.O.T levels when compared with control(P<0.001).while kasis bhasma high dose
treatment group(1000mg/kg) only shows a significant increase in SGOT value. The
SGOT value of control 130.9±0.50 IU/L whereas S.G.O.T value of kasis and swarna
makshika bhasma treated groups significantly increased up to 195±0.40 IU/L and
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188±0.21 IU/L respectively. Elevated levels of serum enzymes were indicative of
cellular leakage and loss of functional integrity of cell membrane in liver.30
Alkaline phosphatase concentration is related to the functioning of
hepatocytes, high level of alkaline phosphatase in the blood serum was related to the
increased synthesis of it by cells lining bile canaliculi usually in response to
cholestasis and increased biliary pressure.31 The results of clinical biochemistry study
showed that all the dose range of  swarna makshika bhasma treated group had a
significant increase in the alkaline phosphatase  levels when compared with
control(P<0.001).While kasis bhasma high dose treatment group(1000mg/kg) only
shows a significant increase in alkaline phosphatase. The alkaline phosphatase value
of control group was 150.6±1.00 IU/L whereas ALP value of swarna makshika
bhasma increased up to 353±0.94 and for kasis bhasma high dose treated group shows
an ALP value of 198±2.14.
Serum bilirubin(total bilirubin, direct bilirubin) is one of the most sensitive
tests employed in the diagnosis of hepatic diseases. Hyperbilirubinemia was observed
due to excessive heme destruction and blockage of biliary tract. As a result of
blockage of the biliary tract there was a mass inhibition of the conjugation reaction
and release of unconjugated bilirubin from damaged and dead hepatocytes.32 The
results of clinical biochemistry study showed that high dose range (500mg/kg,
1000mg/kg) of swarna makshika bhasma treated group had a significant increase in
the total bilirubin levels when compared with control (P<0.001).the total bilirubin
value for control was 0.53±0.005. Whereas TBL value for swarna makshika treated
group increased significantly up to 1.1±0.006.However all dose range of kasis bhasma
treated group doesn’t shows any rise in value of total protein.
ORGAN WEIGHT DATA ANALYSIS
The liver, kidneys and brain of all animals are subjected to be trimmed of any
adherent tissue, as appropriate, and their wet weight taken as soon as possible after
dissection to avoid drying. Table 6.8 represents the changes in weight of different
organs for different doses of both bhasmas. The organs such as liver, kidney, brain of
swarna makshika and kasis bhasma treated group doesn’t showed any significant
increase in organ weight when compared to control, except the rats receiving the dose
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of 1000mg/kg of swarna makshika bhasma shows a significant increase in the liver
weight (P<0.01).
HISTOPATHOLOGICAL STUDIES
The representative microscopic findings in the organs of the rats for
neurotoxicity study in combination with a repeated dose systemic toxicity
(hepatotoxicity and nephrotoxicity) study, oral treatments of swarna makshika and
kasis bhasma are shown in Figure 6.1 to Figure 6. 3.
Effect on liver
Liver biopsies of two different bhasma treated rats are shown in figure. The
results of pathological study of liver when compared with the control goup showed
that swarna makshika bhasma high dose(1000mg/kg) treatment groups had
significant changes in the liver pathology, includes focal periportal inflammation by
chronic inflammatory cells composed chiefly of lymphocytes .the hepatiocytes,
hepatic sinusoids and central veins appear normal. Whereas all the dose range kasis
bhasma treated groups and low dose (250 ,500mg/kg) swarna makshika bhasma
treated rats show normal lobular architecture of liver with normal central portal vein,
radiating plates of hepatocytes and peripheral portal tracts composed of hepatic artery,
bile ductile and distal portal vein. No focal or diffuse foci of necrosis of hepatocytes,
and infiltration of chronic inflammatory cells were observed.
Effect on kidney
Kidney biopsy of all the dose range of kasis and swarna makshika bhasma
treated rats when compared with control shows normal architecture composed of
normal renal glomeruli, collecting tubules, interstitial tissue and blood vessels. There
were no foci of necrosis, degeneration or fibrosis in the interstitium.
Effect on brain
Brain biopsy of all the dose range of kasis and swarna makshika bhasma
treated rats when compared with untreated group shows normal architecture
composed of normal cell bodies of neurons and the glial cells with normal fibrillary
cytoplasm and normal choroid plexus.
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The results of detailed clinical studies and functional tests (rotarod test and
locomotor activity test) revealed that kasis bhasma given in high doses are susceptible
to neurotoxicity or CNS depressant action, kasis bhasma high dose treatment groups
(500mg/kg and 1000mg/kg) showed  decrease in motor activity, muscle strength and
exploratory behavior. This may be due to over dose and excessive absorption of iron
in to mucosal cells of the duodenum and jejnum results in an increased free iron
concentration in blood.8 Excessive absorption of kasis bhasma may be due to the
presence of organic acids in its preparation process. The organic acids and reducing
agents (all acid in character) that promote iron absorption appear to do so by keeping
the PH of the intestine down for a longer time.9
Increased free iron concentration in blood may lead to the dysregulation of
brain iron homeostasis .dysregulation of iron homeostasis may results in the
accumulation of iron in the brain cells. Excessive cellular iron is harmful to brain cells
and promotes ROS formation through Fenton chemistry. Which may results in the
development of neurodegenerative disorders like AD, PD and ALS. However, neither
the mechanisms underlying iron accumulation nor its complete role in the
pathogenesis of the diseases are clear.12
Whereas all the dose range tested for swarna makshika bhasma doesn’t
produce any significant difference in the detailed clinical and functional tests when
compared with the control. No signs of neurotoxicity were observed for swarna
makshika bhasma treated groups.
Results of clinical biochemistry, organ weight analysis and histopathological
studies revealed that swarna makshika bhasma at high doses are highly susceptible to
hepatotoxicity. Impairment in the hepatic functions in toxicity study can be explained
as ferrous iron is absorbed in to mucosal cells of the duodenum and jejunum and is
oxidized to ferric iron and bound to ferritin, it is then slowly released in to the plasma
where it is bound to transferrin, a specific iron binding globulin, and transported to
tissues. Iron bound to transferrin is non toxic with over dosage free iron that exceeds
the iron binding capacity of transferrin, and high ferritin levels cause tissue damage
.free iron injures hepatic cells and cause hepatotoxicity.28
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Normally high dose iron preparations produce nephrotoxicity. However no
sign of nephrotoxicty was observed in clinical biochemistry, organ weight analysis
and histopathological studies for all dose range of both swarna makshika and kasis
bhasma treated groups when compared with control group.33
Mortality was not observed for all the dose range of kasis bhasma and swarna
makshika bhasma treated groups.
CHAPTER - 7
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CHAPTER 7
CONCLUSION
Ayurvedic is largely practiced using ancient protocols and parameters. Though
there is a need of scientific scrutiny of its principles of treatment, very few attempts
have been made for its scientific and systemic validation.  In the present investigation
we tried to assess the toxicity profile of two iron containing bhasmas, swarna
makshika and kasis bhasma. No significant Adverse Effect was observed for low dose
range of swarna makshika and kasis bhasma tested animal. The higher dose range
tested was well above and at an adequate safety distance of the recommended dose in
humans. Though the animals treated with high dose of swarna makshika bhasma
showed hepatotoxicity and for kasis bhasma high dose treated groups shows
neurotoxicity or CNS depressant action.
Thus in conclusion ,  present study indicates that there are chances of
hepatotoxicity and neurotoxicity along  with the  clinical administration  of higher
doses of swarna makshika and kasis bhasma  respectively .while  low  doses of both
bhasmas was found to be safe.  So both bhasmas are considered to be safe at clinically
administered doses (9mg/kg for S.M.B and 4.5mg/kg for K.B). However, further
detailed studies are required to know the long term chronic toxicity of swarna
makshika and kasis bhasma.
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